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Flavonoinds as Modulators of Amyloid Precursor Protein Metabolism and Alzheimer
Disease Pathology
Kavon Rezai-Zadeh

ABSTRACT

Alzheimer disease (AD) is a progressive neurodegenerative disorder
pathologically characterized by deposition of β-amyloid (Aβ) peptides as plaques in the
brain. Central to this AD pathology is mismetabolism of the amyloid precursor protein
(APP). Recent studies suggest that flavonoids, a class of secondary plant metabolites,
may be useful for the prevention and treatment of a variety of neurodegenerative diseases.
The studies detailed herein, investigate the ability of two such classes of flavonoids, green
tea derived catechins and 5,7-dihydroxyflavones, to modulate APP metabolism in
“Swedish” mutant APP (APPsw) models of AD. Studies showed that green tea derived ()-epigallocatechin-3-gallate (EGCG) effectively reduced Aβ generation and resultant
amyloidosis both in vitro and in vivo. In concert with these findings, EGCG markedly
promoted non-amyloidogenic APP proteolysis via activation of the putative α-secretase,
a-disintegrin-and-metalloprotease-10 (ADAM10). Furthermore, luteolin and various
related 5,7-dihydroxyflavones, effectively reduced Aβ generation and resultant
amyloidosis both in vitro and in vivo, as well. Data revealed that luteolin decreased
amyloidogenic γ-secretase APP proteolysis via presenilin-1 (PS1) carboxyl-terminal
vii

fragment (CTF) phosphorylation. Elucidation of these flavonoids’ cellular/molecular
mechanisms also revealed their potential for opposing neurofibrillary tangle (NFT)
pathology, another hallmark of AD. These data raise the possibility that flavonoid
administration to AD patients may prove to be viable and effective prophylactic strategy.

viii

CHAPTER 1

INTRODUCTION

1.1 Alzheimer disease
As first characterized by Alois Alzheimer in 1906, Alzheimer disease (AD) is a
progressive neurodegenerative disorder pathologically distinguished from other forms of
dementia by the presence of amyloid plaques and neurofibrilary tangles (NFTs) in the
brain. As a result of the atrophy that occurs in both cortical and subcortical regions,
patients lose their cognitive and emotional ability to function independently and safely.
Although the course of the disease is progressive, there is great variability in the rate of
decline of different cognitive abilities and skills, emotional responses, and personal
functioning (Eisdorfer et al., 1992; Loewenstein et al., 1995). Accordingly, AD becomes
a devastating experience for patients coping with the illness as well as family members,
who often suffer depression, health problems, increased mortality, and other negative
outcomes because of the strains of caregiving. There is no cure or effective treatment for
AD at this time.
AD has emerged as a national and international pandemic. It is the most common
form of dementia, affecting an estimated 5.2 million Americans this year alone, and that
number is projected to increase to more than 13.2 million persons by 2050 (Herbert et al.,
2003; Plassman et al., 2007). There were an estimated 30 million affected individuals in
the world in 2000, and that number is also projected to increase to over 85 million. Many
risk factors have been implicated by epidemiological study, but age remains the most
significant. The occurrence of AD is rare before age 65, affecting less than 1 person per
1

1000. The prevalence is about 2.5-3% at age 65, and it roughly doubles every five years,
until age 85-90, where the prevalence approaches 50% and appears to plateau (Petersen,
2000; Tanzi, 2000). However, prevalence is expected to increase as diagnosis of the
disease improves and general medicine prolongs longevity. The public health challenge
is significant.
AD is classified into 2 major subcategories, early-onset or familial Alzheimer
disease (EOAD/FAD) and late-onset or sporadic Alzheimer disease (LOAD or SAD),
with 60 to 65 years as the age cutoff. EOAD/FAD accounts for about 5% of all cases.
While EOAD/FAD is considered entirely heritable, genetic factors are also believed to
account for 5-10% of LOAD/SAD cases (Rocchi et al., 2003; Tanzi, 2000). Of the genes
linked to AD, amyloid precursor protein (APP), presenilin-1 and -2 (PS1 and PS2), and
apolipoprotein E (APOE), APP on chromosome 21 was the first identified (Goate et al.,
1991; Levy-Lahad et al., 1995; Strittmatter et al., 1993). Interestingly, nearly all
individuals with Down syndrome (trisomy 21) who survive into their thirties or longer
develop a form of AD (Selkoe et al., 2001; Wisniewski et al., 1985). It is now well
known that APP metabolites, 39-43 amino acid β-amyloid (Aβ) peptides, comprise a
large component of the amyloid plaques deposited in the brains of AD patients (Glenner
and Wong, 1984; Masters et al., 1985; Roher et al., 1993).

1.2 APP metabolism
APP is a 695-770 amino acid transmembrane protein highly expressed in the
brain. There are 3 major APP isoforms generated by alternative splicing (APP695,
APP751, APP770), with APP695 being the predominant isoform in neurons. APP exhibits a
2

rapid turnover rate (half-life of ~2-4 hours) in neuronal tissue as it is trafficked through
secretory and endocytic pathways (LeBlanc et al., 1996). Although its exact endogenous
function has yet to be fully established, APP has been implicated as a mediator of
synaptic plasticity (Priller et al., 2006; Turner et al., 2003). Interestingly, both APP
knock-out and overexpressing transgenic mice exhibit learning impairments (Matsuyama
et al., 2007; Phinney et al., 1999). Proteolysis of APP is the fundamental process for the
production of the Aβ peptides implicated in AD pathology (Funamoto et al., 2004; Golde
et al., 2000; Sambamurti et al., 2002). APP metabolites arise from the coordinated
proteolytic action of α, β and γ-secretases (Figure 1). In the amyloidogenic pathway, Aβ
peptides are produced by the initial action of β-secretase (BACE) cleavage, which creates
an Aβ-containing carboxyl-terminal fragment known as β-CTF, or C99 (Sinha and
Lieberburg, 1999; Yan et al., 1999). This proteolysis also generates an amino-terminal,
soluble APP-β (sAPP-β) fragment, which is released extracellularly. Intracellularly, βCTF is then cleaved by a multi-protein γ-secretase complex, that results in generation of
the Aβ peptide and a smaller γ-CTF, also known as C57 (De Strooper et al., 1998; Steiner
et al., 1999). Conversely, in the non-amyloidogenic pathway, APP is first cleaved at the
α-secretase site, which results in release of amino-terminal soluble APP-α (sAPP-α) and
the generation of an α-CTF or C83 (Hooper et al., 2002), events that are indicative of αsecretase activity (Hooper et al., 2002). Because of the limiting amount of APP in the
cell and the failure to saturate the BACE pathway during APP overexpression, it is
believed that the amyloidogenic and non-amyloidogenic pathways compete for substrate
in the process of APP proteolysis (Gandhi et al., 2004). Therefore, it is often inferred that
3

Figure 1
APP metabolism. Antibody binding sites for amino-terminal APP antibody 22C11,
carboxyl-terminal APP antibodies 369 and C8, and amino-terminal Aβ antibody 6E10 are
as indicated. Adopted from Yan and colleagues (1999).
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extracellular elevation of sAPP-α (non-amyloidogenic pathway product) can be taken as
indirect evidence of inhibition of BACE and the resulting amyloidogenic pathway.
Aβ metabolism is also quite rapid (half-life of ~2-4 hours) and tightly regulated
(Cirrito et al., 2003). In addition, its native physiological role also remains elusive.
Moreover, its primary sequence is not well-conserved with APP across species (Zheng
and Koo, 2006). Aβ peptides can be degraded by various proteases including, insulin
degrading enzyme (IDE) and neprilysin (Iwata et al., 2000; Kurochkin and Goto, 1994).
Furthermore, peptides can be shuttled into the endocytic/lysosomal pathway and
degraded or exported into the periphery for subsequent degradation via the low density
lipoprotein receptor related protein (LRP) (Deane et al., 2004; Kang et al., 2000; Qiu et
al., 1999). Interestingly, endosomal abnormalities are among the earliest evidenced
pathological dysfunctions in AD (Cataldo et al., 1995; Nixon et al., 2000).

1.3 Amyloid hypothesis
The Aβ peptide has long been the prime suspect in pathogenesis of AD, as
aggregated strands of the peptide, called fibrils, are the main constituents of amyloid
plaques. As the major amyloidogenic forms of the peptide (Aβ1-40,42) accumulate both
inside and outside of neurons, amino acid residues begin to link together, forming
oligomers, which subsequently form protofibrils and fibrils rich in β-sheet secondary
structures (Harper et al., 1997; Soto et al., 1995; Teplow, 1998). The conformational
change driven-insolubility of these stacked sheets eventually causes the oligomers to
precipitate out of the cellular milieu. These precipitated oligomers, protofibrils, and

5

fibrils subsequently combine with other excreted cellular components to form a thick,
viscous buildup called an amyloid plaque (Sipe and Cohen, 2000).
From their generation to their deposition as amyloid plaques, Aβ peptides can
potentially trigger a toxic cascade that contributes both directly and indirectly toward
neuronal dysfunction and death. One of the most widely held theories of the
pathogenesis of AD that encapsulates this sentiment is the “amyloid hypothesis.” As first
proposed by Hardy and Allsop (1991), the hypothesis purported that mismetabolism and
deposition of Aβ peptides are the principal etiopathological events in AD. As research
has expanded what is known of AD pathophysiology over the past two decades
proponents have amended the hypothesis accordingly. A more contemporary view
emphasizes the role of soluble oligomeric forms of Aβ as etiological agents of the
disease, rather than the deposited fibrils or plaques. Recent research has further
elucidated these oligomers’ ability to disrupt synaptic functioning both in vitro and in
vivo (Cleary et al., 2005; Klyubin et al., 2005; Shankar et al., 2007). In particular, soluble
Aβ oligmers termed “amyloid-derived diffusible ligands” (ADDLs) were detected to be
at least an order of magnitude higher in AD patients and may account for the imperfect
correlation between amyloid plaques and diagnosis (Gong et al., 2003; Klein, 2002).
However, previous research suggesting the potential neurotoxicity of insoluble fibrillar
forms of Aβ should not be forgotten (Loo et al., 1993; Lorenzo et al., 1994). In view of
this, it may be that both soluble and insoluble forms of Aβ contribute, via discrete
mechanisms, to the continuum of AD pathology.

6

1.4 AD pathology
While the exact cause of neurodegeneration in AD is uncertain, it is has been
suggested to involve the interplay of apoptosis, oxidative stress, inflammation, NFT
formation, excitotoxcity, and glucose metabolism dysfunction, all of which may be
mediated by Aβ-dependent mechanisms. As touched upon in the section above, both
oligomeric and fibrillar forms of Aβ1-42 have been extensively reported to induce
apoptosis in cultured neurons and neuron-like cells. Apoptosis is a tightly regulated
process in which a series of biochemical events promote morphological changes in
cellular structures that ultimately result in death of a cell. It has been postulated that Aβ
directly interacts with neurons to propagate intracellular signaling, which triggers these
biochemical events via activation of a caspase cascade (Awasthi et al., 2005; Harada and
Sugimoto, 1999). Aβ-mediated oxidative stress may also induce apoptosis (Butterfield et
al., 2002; Shearman et al., 1994). Aβ has been shown to readily react with large metal
ions such as, copper (Cu2+), iron (Fe3+), and zinc (Zn2+), and through redox chemistry
generate hydrogen peroxide (H2O2) (Opazo et al., 2002). This reactive oxygen species
(ROS) can damage cells by both oxidation of lipoproteins of cellular membranes and
mitochondrial and nuclear DNA. In addition, H2O2 has been shown to directly mediate
apoptosis by modulation of the regulatory proteins Bax and Bcl-2 and activation of
caspase-3 (Jiang et al., 2003; Milton, 2004). Another source of ROS, while secondary, is
believed to come from microglial activation during inflammation.
An abundance of post-mortem and basic research studies have confirmed that
inflammatory processes play a role in the pathology of AD. Microglial and astroglial
activation in close proximity to amyloid plaques are two of the most consistently
7

evidenced markers of inflammation. For this reason, many current research efforts focus
on the complex cascade of potentially deleterious inflammatory events, especially
activation of microglia, the resident immune cells of the central nervous system (CNS), to
identify and clarify the neurodegenerative effects caused by the immune response to Aβ.
Chronic activation of microglia is believed to trigger and maintain an inflammatory
response, which may ultimately lead to neuronal cell death such as that observed in AD.
In fact, this chronic activation may expose the CNS to elevated levels of a wide array of
potentially neurotoxic molecules including pro-inflammatory cytokines, complement
proteins, proteinases, excitotoxins, and (as mentioned above) ROS . Conversely, an
alternative view suggests that dysregulation of microglial activation may prevent
appropriate inflammatory responses necessary to respond to neuroinsults such as
accumulation of Aβ. Accordingly, the debate over whether this inflammatory component
of AD is intrinsically beneficially of harmful continues (Akiyama et al., 2000; Streit,
2005).
Another major pathologically contributing process in AD is the formation of
NFTs inside neurons. While generation and deposition of Aβ peptides as amyloid
plaques typically occurs before NFT formation, the latter follows closely with, but
supposedly independently of cerebral amyloidosis. However, a growing number of
reports have suggested that these two pathologies may be linked, as Aβ generation and
deposition may promote NFT formation (Alvarez et al., 1999; Busciglio et al., 1995;
Calhoun et al., 1998; Greenberg and Kosik, 1995). The main protein constituent of the
NFTs is the microtubule associated protein (MAP) tau. The tau protein forms an essential
part of the neuron cytoskeleton, aiding with the support of the shape of the cell and
8

facilitating intercellular transport. In the case of AD and various other tauopathies, tau
has been found to be abnormally phosphorylated/dephosphorylated at specific residues by
several possible neuronal kinases/phosphatases both in vitro and in vivo, which is
hypothesized to ultimately lead to conformational abnormality, dysfunction, and
aggregation (Arendt et al., 1998; Lee et al., 2000; Wang et al., 1998; Yamamoto et al.,
2002). Unfortunately, once NFTs have formed anti-Aβ therapeutic strategies may prove
to be ineffective against their underlying pathological mechanisms and removal.
Overstimulation of excitatory N-methyl-D-aspartate receptors (NMDA-Rs) has
also been implicated in the pathology of AD (Doraiswamy, 2003; Mattson and Chan,
2003). This process, termed excitotoxicity, progresses as NMDA-Rs begin to indirectly
mediate calcium (Ca2+) transport into neurons. This influx is routinely used to trigger the
release of neurotransmitters from synaptic vessicles. However, as Ca2+ accumulates
within the neuron, Ca2+-dependent calpains and endonucleases may begin to degrade
essential proteins and DNA, respectively in line with apoptotic mechanisms. Ca2+-related
mitochondrial dysfunction may also generate significant amounts of ROS within neurons
(Rego and Oliveira, 2003). While glutamate typically functions as the excitatory ligand,
De Felice and colleagues (2007) recently reported that ADDLs may bind to or in close
proximity to NMDA-Rs to propagate excitotoxic effects.
Multiple lines of evidence from both clinical and basic research studies have also
suggested that neuronal glucose metabolism is impaired in AD. The brain almost
exclusively utilizes glucose as its source of energy. In view of this, it is becoming
increasingly evident that neuronal glucose metabolism is essential for maintaining
synaptic plasticity required for memory formation and retrieval. Positron emission
9

tomography (PET) employing (18F)fluoro-2-deoxyglucose (FDG) has confirmed glucose
hypometabolism in cortical regions of AD patients’ brains, although it remains unclear
whether neuronal populations are specifically affected (Friedland et al., 1983; Minoshima
et al., 1997; Swerdlow et al., 1994). Remarkably, Aβ may also be linked to processes
that govern this metabolism. Previous in vitro studies suggest that Aβ1-40,42 may inhibit
glucose metabolism by competitively binding to insulin receptors and preventing their
signaling (Xie et al., 2002). Conversely, other studies have suggested that Aβ promotes
glucose metabolism via activation of hypoxia-inducible factor-1 (HIF-1) (Soucek et al.,
2003). However, this metabolic activation may still ultimately result in neuronal death
through glucose starvation (Schubert, 2005).
Whether one specific process confers more neurotoxicity than the other will
continue to be an area on controversy. Yet, just as the impact of genetic and
environmental risk factors may vary in each individual, so may the relative effects of
each specific pathological process. Only through continued research will effective
therapies capable of preventing, halting, or reversing these pathological processes be
identified.

1.5 Flavonoids
The intense search for small-molecular compounds that may modulate AD
pathology has advanced the analysis of specific dietary derived substances, which
epidemiological studies suggest are beneficial against disease-related neurodegeneration
and aging processes (Bastianetto, 2002; Dai et al., 2006; Genkinger et al., 2004; Laurin et
al., 2004; Sun et al., 2002). Recent research has focused on the analysis of flavonoids, a
10

group of phenolic phytochemicals common in vascular plants and abundant in particular
spices, vegetables, and fruits. Similar to alkaloids, but less toxic, flavonoids are
secondary metabolites and as such do not directly contribute to plant development,
growth, or reproduction. The function or importance of these secondary metabolites is
usually of an ecological nature. Both flavonoids and alkaloids can be used as defenses
against predators, parasites and diseases, or even for interspecies competition. For these
reasons, many flavonoids possess intrinsic anti-microbial and anti-fungal properties
(Nijveldt et al., 2001). Flavonoids are also considered important constituents in the
human diet, although their daily intake varies with dietary habits (Nielsen et al., 1999;
Sampson et al., 2002). Numerous medicinal properties have been ascribed to flavonoids,
notably for their anti-oxidant (Saija et al., 1995; van Acker et al., 1996), anti-carcinogenic
(Kanadaswami et al., 2005; Ren et al., 2003), and anti-inflammatory activity (Pelzer et
al., 1998; Middleton, 1998). While the molecular basis for these properties has not been
fully established, a growing number of studies have begun to dissect out the disease
modifying mechanisms of these compounds.
Over the past decade, intense focus has been given to investigating the processes
of APP and Aβ metabolism as possible targets for AD therapy (Hardy and Selkoe, 2002).
In this regard, few flavonoids have been analyzed for their efficacy in the modulation of
these pathological events. In particular, the naturally occurring compounds curcumin,
from the spice turmeric, and resveratrol, from red wine, have been reported to alter APP
and Aβ metabolism in models of AD (Marambaud et al., 2005; Yang et al., 2005). Other
naturally occurring compounds achieving worldwide popularity for their therapeutic
application are from green tea. Green tea contains a unique subset of flavonoids,
11

catechins, which are believed to be the active components accounting for the therapeutic
properties of green tea. Arguably one of the most promising green tea compounds being
analyzed is (-)-epigallocatechin-3-gallate (EGCG), which has been extensively studied
due largely to its reported anti-carcinogenic effects (Lin and Liang, 2000; Moyers and
Kumar, 2004). Interestingly, EGCG has been found to modulate protein kinase C (PKC)
activity and consequently increase secreted levels of sAPP-α, which suggests a potential
underlying APP metabolic mechanism (Levites et al., 2002, 2003). Multiple in vitro
studies have also evidenced EGCG’s ability to act as a free radical scavenger.
Additionally, EGCG has been shown to inhibit various activities of pro-inflammatory
cytokines (Ahmed et al., 2002; Han, 2003; Li et al., 2004). Accordingly, signal transducer
and activator of transcription 1 (STAT1) and nuclear factor κB (NFκB) responses are
inhibited by EGCG (Aktas et al., 2004; Han, 2003). Studies investigating glutamateinduced Ca2+ influx have shown that EGCG may be an effective regulator of this process
as well (Bae et al., 2002; Lee et al., 2004). EGCG has also been reported to promote
glucose metabolism by increasing insulin sensitivity (Lin et al., 2008; Potenza et al.,
2007). Elucidation of these molecular actions of EGCG substantiates the compound as a
versatile modulator of cellular responses that may contribute to AD pathogenesis.
Importantly, the studies mentioned above provide a criterion for selecting future
flavonoids to screen for their efficacies as modulators of APP metabolism and ultimately
potential therapeutics for AD. For instance, the flavonoid luteolin, largely found in
parsley, peppers, and celery, has been reported to be a free radical scavenger (Horvathova
et al., 2004; Reddy et al., 2005), an anti-inflammatory agent (Odontuya et al., 2005; Ueda
et al., 2002), a regulator of Ca2+influx (Kimata et al., 2000), and potential promoter of
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glucose metabolism (Zarzuelo et al., 1996). If luteolin should also prove to be a potent
modulator of APP metabolism, it may be an ideal candidate compound for opposing AD
pathogenesis. In the chapters to come the anti-amyloidogenic properties of EGCG and
luteolin are established and their underlying mechanisms fully explored in “Swedish”
mutant APP (APPsw; Mullan et al., 1992) models of AD.
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CHAPTER 2

MATERIALS AND METHODS

2.1 Cell culture

2.1.1 Immortalized murine cell lines
Both parental murine neuroblastoma (N2a) and N2a cell lines stably transfected
with the “Swedish” mutant form of APP (SweAPP N2a cells; APP695), a well established
in vitro model of AD, were kind gifts from S. Gandy (Thomas Jefferson University,
Philadelphia, PA, USA). SweAPP N2a cells were maintained in Dulbecco’s modified
Eagle’s medium (DMEM), 10% fetal calf serum (FCS), and 200 µg/ml G418. Prior to
treatment N2a cells were differentiated in serum-free Neurobasal medium supplemented
with 300 µM dibutyryl-cAMP for 4 hours. N9 microglial cell lines, originally generated
from myc-immortalized mice, were a kind gift from Dr. P. Ricciardi-Castagnoli
(Universita Degli Studi di Milano-Bicocca, Milan, Italy). N9 microglial cells were
maintained in DMEM, 5% FCS and 2 mM glutamine. All cultures were incubated in
serum-free medium at 37° C with 10% CO2 during treatment.

2.1.2 Murine-derived primary cell lines
Murine primary neuronal cells were prepared as previously described (Tan et al.,
2000). Briefly, cerebral cortices were isolated from mouse embryos, between 15 and 17
days in utero, and were mechanically dissociated in trypsin (0.25%) individually after
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incubation for 15 minutes at 37 °C. Cells were collected after centrifugation at 1,200 x g,
resuspended in DMEM supplemented with 10% fetal calf serum, 10% horse serum,
uridine (33.6 µg/mL; Sigma, St. Louis, MO, USA), and fluorodeoxyuridine (13.6 µg/mL;
Sigma), and seeded in 24-well poly-D-lysine coated culture plates at 2.5 x 105 cells per
well. When neuronal cells were isolated from transgenic APPsw (Tg mice APPsw), to
verify the presence of the transgene, PCR genotype analysis was performed as previously
described (Tan et al., 2002). Murine primary microglial cells also isolated as previously
described (Tan et al., 2000). Briefly, cerebral cortices from newborn mice (1-2 day-old)
were isolated under sterile conditions and were kept at 4°C before mechanical
dissociation in trypsin (0.25%). The resulting cultures were plated in 75 cm2 poly-Dlysine coated flasks and grown in RPMI 1640 medium supplemented with 5% fetal calf
serum, 2 mM glutamine, 100 units/ml penicillin, 0.1 µg/mL streptomycin, and 0.05 mM
2-mercaptoethanol. Primary cultures were kept for 14 days so that only glial cells
remained and microglial cells were isolated by shaking flasks at 200 rpm in a Lab-Line
incubator-shaker. Following isolation, glial cells were seeded in 24-well poly-D-lysine
coated culture plates at 2.5 x 105 cells per well. To verify their glial status, cells were
subsequently stained for the microglial marker Mac-1 (CD11b/CD18; Boehringer
Mannheim, Indianapolis, IN, USA). All cultures were incubated in their respective
complete medium at 37° C with 10% CO2 during treatment.

2.1.3 Lysate preparation
All cultured cells were lysed in ice-cold lysis buffer (20 mM Tris, pH 7.5, 150
mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% v/v Triton X-100, 2.5 mM sodium
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pyrophosphate, 1 mM β-glycerolphosphate, 1 mM Na3VO4, 1 µg/mL leupeptin, 1 mM
PMSF) for 5 minutes followed by scraping. Lysates were collected and centrifuged at
14,000 x g for 15 minutes at 4°C. Protein levels in cell lysate supernatants were
determined and normalized by bicinchoninic acid assay (BCA; Pierce Biotechnology,
Rockford, IL, USA) in accordance with the manufacturer’s instruction.

2.2 Mice

2.2.1 Housing and maintanence
Tg APPsw mice of a hybrid B6/SJL background (line 2576; Hsiao et al., 1996)
were purchased from Taconic (Germantown, NY, USA). Both non transgenic (NT) and
Tg APPsw mice with a mixed background of 56.25% C57, 12.5% B6, 18.75% SJL, and
12.5% Swiss-Webster were kindly provided by G. Arendash (Johnnie B. Byrd Sr.
Alzheimer’s Center and Research Institute, Tampa, FL, USA). Transgene expression in
each of the transgenic mice was confirmed by genotyping as previously described
(Arendash et al., 2006; Tan et al., 2002). All animals were given ad libitum access to
water and chow and maintained on a 12 hour light/dark cycle. All animals were housed
in the College of Medicine Animal Facility at the University of South Florida (USF) and
all experiments were in compliance with protocols approved by the USF Institutional
Animal Care and Use Committee.

2.2.2 Stereotactic intracerebroventricular injection
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Mice were anesthetized using isoflurane via chamber induction at 4-5% with intubation
and maintenance at 1-2%. Reflexes were checked to ensure that all animals were
unconscious. Mice were positioned on a stereotaxic frame with ear-bars plugged and
jaws fixed to a biting plate. Under a surgical microscope, a small incision was made to
expose the skull, generally 1 cm above and below bregma. Using a DremelTM tool fitted
with a small burr bit, a small hole was made in the skull (0.6 mm posterior and 1.2 mm
left lateral to the bregma). Injections were made in the left lateral ventricle from
delimited coordinates relative to bregma (− 0.6 mm anterior/posterior, + 1.2 mm
medial/lateral, and − 3.0 mm dorsal/ventral) using stereotaxic device (Stoelting Lab
Standard, Wood Dale, IL, USA) and an attached probe holder. Treatment volumes of
5µL were administered at the rate of 1 µL/min using a Hamilton syringe (Sigma).
Correctness of the injection was confirmed by trypan blue dye administration and
histological examination.

2.2.3 Brain homogenate and tissue section preparation
Mice were anesthetized with isofluorane and transcardially perfused with ice-cold
physiological phosphate buffered saline (PBS) containing heparin (10 U/mL). Brains
were rapidly isolated and quartered using a mouse brain slicer (Muromachi Kikai, Tokyo,
Japan). First and second anterior quarters were homogenized for western blot and ELISA
analysis. Briefly, brain quarters were homogenized in ice-cold lysis buffer by sonication
for 3 minutes. The resulting homogenates were allowed to stand for 15 minutes at 4°C
and were subsequently centrifuged at 14,000 g for 15 minutes at 4°C. Protein levels in
cell lysate supernatants were determined and normalized by BCA assay in accordance
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with the manufacturer’s instruction. Third and fourth posterior quarters were used for
microtome or cryostat sectioning. Briefly, brain quarters were fixed in 4%
paraformaldehyde in PBS at 4°C overnight and routinely processed in paraffin at the core
facility of Department of Pathology in the College of Medicine at USF. Following
embedment in appropriate medium, five coronal sections from each brain quarter (5 and
25µm thickness for paraffin and cryostat) were cut with a 150 µm interval.

2.3 ELISA

2.3.1 Aβ1-40 and Aβ1-42
Aβ1-40 and Aβ1-42 species were quantified in samples using Aβ1-40 and Aβ1-42
ELISA kits (IBL-American, Minneapolis, MN, USA) in accordance with the
manufacturer’s instruction, except that standards include 5 M guanidine buffer. Soluble
Aβ species were detected in brain homogenates prepared with lysis buffer described
above following a 1:10 dilution in lysis buffer. Insoluble Aβ species were detected by
acid extraction of brain homogenates in 5 M guanidine buffer (Johnson-Wood et al.,
1997), followed by a 1:10 dilution in lysis buffer. ELISA values were reported as %
control or pg of Aβ1-x/mg of total protein, as determined by BCA assay.

2.3.2 Total Aβ
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Total Aβ1-40,42 species were quantified in samples as previously described (Tan et
al., 2002). Briefly, 96-well immunoassay plates were coated with monoclonal anti-Aβ1-17
antibody (6E10; 2 µg/mL in PBS; Signet Laboratories, Dedham, MA, USA) overnight at
4 °C. Plates were washed with 0.05% Tween 20 in PBS 5 times and incubated with
blocking buffer (PBS with 1% bovine serum albumin (BSA), 5% horse serum) for 2
hours at room temperature. Conditioned media, brain homogenates, or standards were
added to the plates, following appropriate dilutions above, and incubated overnight at 4
°C. Following 3 washes, biotinylated anti-Aβ17–26 monoclonal antibody (4G8; 0.5 µg/mL
in PBS with 1% BSA; Signet Laboratories), was added to the plates and incubated for 2
hours at room temperature. After 5 washes, streptavidin-horseradish peroxidase (HRP)
(1:200 diluted in PBS with 1% BSA) was added to the 96-well plates for 30 minutes at
room temperature. Tetramethylbenzidine (TMB) substrate was added to the plates and
incubated for 15 minutes at room temperature. Stop solution (2N H2SO4) was added to
stop the colorimetric reaction and optical density was determined immediately by a
microplate reader at 450 nm. ELISA values from were reported as % control or pg of
Aβ1-x/mg of total protein, as determined by BCA assay.

2.3.3 sAPP-α
sAPP-α was quantified as previously described by Olsson and colleagues (2003)
with minor changes. Briefly, 96-well immunoassay plates were coated with monoclonal
amino-terminal APP antibody (22C11; Roche, Basel, Switzerland) overnight at 4°C.
Plates were washed with 0.05% Tween 20 in PBS 5 times and incubated with blocking
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buffer (PBS with 1% BSA, 5% horse serum) for 2 hours at room temperature.
Conditioned media, brain homogenates, or standards were added to the plates, following
appropriate dilutions above, and incubated overnight at 4 °C. Following 3 washes,
biotinylated 6E10 (Signet) was added to the plates and incubated for 2 hours at room
temperature. After 5 washes, streptavidin-HRP (1:200 diluted in PBS with 1% BSA) was
added to the 96-well plates for 30 minutes at room temperature. TMB substrate was
added to the plates and incubated for 15 minutes at room temperature. Stop solution (2N
H2SO4) was added to stop the colorimetric reaction and optical density was determined
immediately by a microplate reader at 450 nm. ELISA values were reported as % control
or µg of sAPP-α/mg of total protein, as determined by BCA assay.

2.4 Western blot
Aliquots from lysates, precipitates, and homogenates corresponding to 50 µg of
total protein were electrophoretically separated using 10% Tris/Glycine or 16.5%
Tris/Tricine SDS-Polyacrylamide gels. Electrophoresed proteins were then transferred to
PVDF or nitrocellulose membranes (Bio-Rad, Hercules, CA, USA), which were
subsequently washed in distilled de-ionized water (ddH2O) and blocked for 1 hour at
room temperature in Tris buffered saline (TBS) containing 5% (w/v) non-fat dry milk.
After blocking, membranes were hybridized with various primary antibodies for 4 hours
at room temperature or overnight at 4°C. Membranes were then washed 3 times for 5
minutes each in ddH2O and incubated for 1 hour at ambient temperature with the
appropriate HRP-conjugated secondary antibody (1:1,000, Pierce). All antibodies were
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diluted in TBS containing 5% (w/v) non-fat dry milk in accordance with the
manufacturer’s suggestions. Blots were washed 3 times for 5 minutes each in ddH2O
prior to being developed using a chemiluminescence luminol reagent (Pierce).

2.4.1 APP metabolite profiling
CTFs of APP were detected by carboxyl-terminal APP antibody (369; a kind gift
from S. Gandy and H. Steiner, Ludwig-Maximilians-University, Munich, Germany).
Briefly, blots were first hybridized with 369 to characterize APP CTFs. Following
development, blots were put in stripping solution (62.5 mM Tris-HCl, pH 6.8, 2% SDS,
and 100 mM 2-mercaptoethanol) and incubated at room temperature for 30 minutes.
After stripping, blots were rinsed with TBST (TBS, 0.1% Tween 20) and re-blocked with
TBSTM (TBST, 5% (w/v) non-fat dry milk), and then re-probed with 6E10.
Alternatively, membranes with identical samples were probed either with antibody 369 or
with antibody 6E10. An ~11 kDa band was positively detected with both 369 and 6E10
antibodies, thereby distinguishing between α-CTFs and β-CTFs. For sAPP-α, cultured
media was collected following treatment according to a modified protocol from Chen and
Fernandez (2004). sAPP-α was extracted using 3K Nanosep centrifugal filters (Pall Life
Sciences, Ann Arbor, MI, USA) and protein concentrate was subjected to western blot
analysis with 6E10 antibody as described above.

2.5 Immunoprecipitation
Aliquots from lysates and homogenates corresponding to 200 µg total protein
were pre-cleared by incubating with 10 µL of a protein A-Sepharose bead slurry (50% in
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PBS, Sigma) for 1 hour with gentle rocking at 4°C. Samples were centrifuged at 14,000
g for 5 minutes, pellets were discarded, and the resulting supernatants were incubated
with various primary antibodies overnight with gentle rocking at 4°C. 50 µL of the
protein A-Sepharose bead slurry was then added to the samples prior to gentle rocking for
4 hours at 4°C. Samples were centrifuged at 14,000 g for 5 minutes, supernatants were
either discarded or retained for immunodepletion experiments, and the resulting pellets
were washed 3 times PBS. Following washing, precipitated samples were subjected to
western blot as described above.

2.5.1 Secreted APP metabolite profiling
sAPP-α, sAPP-β, and Aβ was detected by incubating pre-cleared cultured media
with various sequential combinations of 6E10 (1:100) and/or 22C11 (1:100) antibodies
overnight with gentle rocking at 4°C. 100 µL of the protein A-Sepharose bead slurry was
then added to the samples prior to gentle rocking for 4 hours at 4°C. Samples were
centrifuged at 14,000 g for 5 minutes, supernatants were either discarded or retained for
immunodepletion experiments, and the resulting pellets were washed 3 times lysis buffer.
Following washing, precipitated samples were subjected to western blot as described
above.

2.6 Secretase activity assay
Secretase activity was quantified in cell lysates using R&D Systems kits
(Minneapolis, MN, USA) based on secretase-specific substrates conjugated to
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fluorogenic reporter molecules (EDANS/DABCYL) in accordance with the
manufacturer’s instructions. Briefly, appropriate amounts of lysates or homogenates,
reaction buffer, and flurogenic substrate were added to 96-well assay plates and
incubated at 37ºC for various periods of time. Following incubation, fluorescence was
monitored (excitation at 335 nm and emission at 495 nm) at room temperature with a
fluorescence microplate reader. Fluorescence was adjusted using appropriate controls
(no lysate or homogenate and no fluorogenic substrate).

2.7 RT-PCR
Analysis of murine ADAM10 was conducted according to previously published
methods (Park et al., 2001; Ehrhart et al., 2005). Briefly, total RNA was isolated from
SweAPP N2a cells and subjected to reverse transcription utilizing a commercially
available kit (cDNA Cycle kit; Invitrogen, Carlsbad, CA, USA) according to the
manufacturer’s instructions on a Bio-Rad iCycler thermocycler. The same machine was
used to amplify murine cDNA by PCR using ADAM10 sense (5'GCCAGCCTATCTGTGGAAACGGG-3') and antisense (5'TTAGCGTCGCATGTGTCCCATTTG-3') primers or γ-actin sense (5'TTGAGACCTTCAACACCC-3') and antisense (5'-GCAGCTCATAGCTCTTCT-3')
primers (0.5 µg/25 µl final reaction volume) using a commercially available kit
(HotStarTaq Master Mix; Qiagen, Valencia, CA, USA) according to the manufacturer’s
instructions. Thermocycler conditions consisted of an initial denaturing step at 95 °C for
15 minutes, followed by 35 cycles of 94 °C for 30 seconds, 50 °C for 1 minute, and 72 °C
for 1 minute, and a final extension step at 72 °C for 10 minutes. Resolution and analysis
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of PCR product (murine ADAM10: 881 bp, murine γ-actin: 357 bp) band densities were
conducted by ethidium bromide-stained agarose gel electrophoresis and identified using
UV transillumination by comparisons with molecular weight markers (Invitrogen).
Samples that were not subjected to reverse transcription were run in parallel as negative
controls to rule out DNA contamination as a template for PCR products (data not shown).
A no template control was also included for each primer set as a further negative control
(data not shown). Amplification of γ-actin was used to normalize for input cDNA.

2.8 RNAi
SweAPP N2a cells were transfected with siRNA pre-designed to knockdown
murine ADAM9, -10, or -17 and GSK-3α or GSK-3β mRNA (Dharmacon Inc.,
Lafayette, CO, USA). SweAPP N2a cells seeded in 24-well poly-D-lysine coated culture
plates at 1 x 105 cells per well and cultured until they reached 70% confluence. The cells
were then transfected with 50–200 nM concentrations of target siRNA or anti-green
fluorescent protein (non-target control; Dharmacon) using Code-Breaker transfection
reagent (Promega, Madison, WI, USA) and cultured for an additional 18 hours in serumfree DMEM. Transfection efficiency was determined to be greater than 70% (data not
shown) using no-RISC siGLOW (fluorescently labeled non-functional siRNA;
Dharmacon). The cells were allowed to recover for 24 hous in complete medium before
treatment. Resulting lysates were also subjected to western blot as described above for
analysis of expression of target proteins.

2.9 Cytotoxicity assay
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Cell death was measured from lactate dehydrogenase (LDH) release detected
directly in cultured media using a CytoTox 96 Non-Radioactive Cytotoxicity Assay kit
(Promega) in accordance with the manufacturer’s instructions. Briefly, appropriate
amounts of cultured media, reaction buffer, and colorimetric substrate were added to 96well assay plates and incubated at 37ºC for various periods of time. Following
incubation, optical density was monitored at 490 nm at room temperature with a
microplate reader. Cytotoxicity values were determined using appropriate controls
(reaction buffer alone and lysis buffer treated cell cultured media).

2.10 Tissue staining

2.10.1 Immunohistochemical
Sections were routinely mounted on slides and air dried or deparaffinized and
hydrated in a graded series of ethanol before preblocking for 30 minutes at room
temperature with serum-free protein block (Dako Cytomation, Carpinteria, CA, USA).
Staining was performed for amyloid pathology using 4G8 antibody (1:100; Signet
Laboratories) and GSK-3 activity using anti-phospho-GSK3α/β (pTyr279/216 ) antibody
(1:50; Sigma) in conjunction with the VectaStain Elite ABC kit (Vector Laboratories,
Burlingame, CA, USA) coupled with diaminobenzidine (DAB) substrate. Stained
sections were rinsed through three rapid changes of 100% ethanol, cleared through three
changes of xylene, then coverslipped with permount. Sections were visualized under
bright-field using an Olympus BX-51 microscope (Tokyo, Japan).
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2.10.2 Thioflavin S
Sections were routinely mounted on slides and air dried or deparaffinized and
hydrated in a graded series of ethanol before staining with fresh-filtered 1% (w/v)
thioflavin S diluted in 70% ethanol for 5 minutes. These sections were then rinsed 3
times for 5 minutes each in 70% ethanol, hydrated for 5 minutes in PBS, and mounted in
Vectashield fluorescence mounting media (Vector Laboratories). Thioflavin S-positive βamyloid plaques were visualized under dark field using an Olympus BX-51 microscope.

2.10.3 Congo red
Sections were routinely mounted on slides and air dried or deparaffinized and
hydrated in a graded series of ethanol before staining. Hydrated sections were then
incubated in an alkaline alcoholic saturated sodium chloride solution (2.5 mM NaOH in
80% alcohol, freshly prepared) for 20 minutes. Following incubation, sections were
stained with a 0.2% Congo red in alkaline alcoholic saturated sodium chloride solution
(freshly prepared and filtered) for 30 minutes. Stained sections were rinsed through three
rapid changes of 100% ethanol, cleared through three changes of xylene, then
coverslipped with permount. Congo red-positive β-amyloid plaques were visualized
under bright-field and polarized light (to confirm green bifringence) using an Olympus
BX-51 microscope.

2.11 Image Analysis

2.11.1 Western Blot
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Densitometric analysis was conducted using the Fluor-S MultiImager with
Quantity One software (Bio-Rad) or ImageJ software (NIH). Images were obtained from
film using a scanner. Protein bands were captured, and a threshold optical density was
obtained that discriminated bands from background. Densitometric values were reported
as area of positive pixels in reference to an internal control.

2.11.2 Tissue sections
Quantitative image analysis (conventional “Aβ plaque burden” analysis) was
performed for 4G8 immunohistochemical, thioflavin S, and Congo red stained sections.
Images were obtained using an Olympus BX-51 microscope and digitized using an
attached MagnaFire imaging system (Olympus). Briefly, images of five 5 or 25 µm
sections (150 µm apart) through each anatomic region of interest (hippocampus or
cortical areas) were captured, and a threshold optical density was obtained that
discriminated staining from background. Manual editing of each field was used to
eliminate artifacts. Data are reported as a percentage of stained area captured (positive
pixels) divided by the full area captured (total pixels). Quantitative image analysis was
performed by a single examiner blinded to sample identities.

2.12 HPLC
HPLC measurements were carried out using a BioLogic HPLC system (Bio-Rad)
equipped with a Duo Flow pump, BioFrac fraction collector, and a Quadtec UV/Vis
detector set to 280 nm. Briefly, samples were injected onto a reverse-phase column
(Agilent, SB-C8 80A 5µm, length 150 mm, i.d. 4.6 mm) through an injection valve with
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a 50 µl sample loop. The mobile phase consisted of an isocratic flow of
water:acetonitrile:trifluoroacetic acid (87/13/.1) pumped at a rate of 1.00 mL/min at 25°C
for 40 minutes. Standard samples of EGCG (Sigma) dissolved in water were run before
and after the experimental samples. Remote control of the HPLC system, data
acquisition and calculation of peak areas will be performed via computer-based data
system (Bio-Rad EZLogic).

2.13 Tau analysis
Pellets from brain homogenates were re-homogenized in 10 volumes of 10%
sucrose lysis buffer solution (10 mM Tris, pH 7.5, 0.8 M NaCl, 1 mM EDTA, 1 mM
EGTA, 2.5 mM sodium pyropgosphate, 1 mM β-glycerolphosphate, 1 mM Na3VO4,
1 µg/mL leupeptin, 1 mM PMSF) and centrifuged at 14,000 x g for 15 minutes. The
resulting supernatants were treated with 1% (wt/v) N-laurylsarcosine (sarkosyl) to obtain
soluble and insoluble fractions for Western blot as previously described (Greenberg and
Davies, 1990). Aliquots corresponding to 100 µg of total protein were subjected to
western blot as described above.

2.14 Radial arm water maze (RAWM)
This water-based task of working memory, which is very sensitive to brain Aβ
levels, was employed as previously described (Arendash et al., 2004; Arendash et al.,
2006). Briefly, the RAWM maze contained 6 swim paths (arms) radiating out of an open
central area, with a hidden escape platform located at the end of one of the arms. Spatial
cues for the maze were provided on the walls surrounding the RAWM task throughout
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testing. In each trial, mice were allowed to swim in the arms for up to 60 seconds to find
the escape platform, which was randomly assigned to an arm each day. During this time,
if mice chose a wrong arm they were gently guided back to the start arm to renew
navigating the maze and an error was recorded. Upon finding the correct arm, mice were
permitted to remain on the platform for 30 seconds prior to the next trial. RAWM testing
consisted of four acquisition trials and one memory retention trial (e.g. five trials, with
each trial starting from a different arm and the remaining arm containing the submerged
platform for that day). For each trial, mice were placed in the water at the entrance of a
start arm of the maze for that day, facing the central swimming area. This start arm was
never the same arm that contained the submerged escape platform, and a different start
arm sequence was randomly selected each day. RAWM testing was conducted over 15
successive days, which were broken into 3 day blocks. The last trial of the four
successive trials (trial 4, T4) and a 30-minute delayed retention trial (trial 5, T5) of the
last 3 blocks were considered as measures of working memory.

2.15 Statistical analysis
All data were normally distributed; therefore, in instances of single mean
comparisons, Levene’s test for equality of variances followed by a t test for independent
samples was used to assess significance. In instances of multiple mean comparisons,
analysis of variance ANOVA was used, followed by post hoc comparison using
Bonferonni’s method. α-levels were set at 0.05 for all analyses. The statistical package
for the social sciences release 10.0.5 (SPSS Inc., Chicago, IL, USA) or Statistica
(StatSoft Inc., Tulsa, OK, USA) was used for all data analysis.
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CHAPTER 3

ANTI-AMYLOIDOGENIC PROPERTIES OF GREEN TEA
EPIGALLOCATECHIN-3-GALLATE (EGCG)

3.1 α-Secretase activation
Therapies that oppose cleavage of APP into Aβ peptides and resultant cerebral
amyloidosis have become a primary focus in the recent years. The main targets have
been β- and γ-secretase, the two proteases that cleave APP at the amino and carboxylterminus of the Aβ peptide, respectively, and hence are directly responsible for Aβ
peptide generation (De Strooper et al., 1998; Sinha and Lieberburg, 1999; Steiner et al.,
1999; Yan et al., 1999). An alternative strategy, namely the activation of α-secretase, has
scarcely been investigated for its therapeutic potential. α-secretase cleaves its APP
substrate within the Aβ peptide domain and precludes peptide generation, thereby
promoting the non-amyloidogenic pathway of APP proteolysis (Hooper and Turner,
2002). α-secretase activation may even have the added advantage of, not only preventing
neurotoxic Aβ peptide formation, but also generating the putatively neuroprotective
sAPP-α (Furukawa et al., 1996; Mattson et al., 1997, 1999, Stein et al., 2004).

3.1.1 a-disintegrin-and-metalloprotease (ADAM) proteins
A number of reports have implicated members of the a-disintegrin-andmetalloprotease (ADAM) family, a group of zinc metalloproteases including ADAM9,
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10, and 17, as putative α-secretase candidates (Hooper and Turner, 2002; Allinson et al.,
2003; Asai et al., 2003). Lammich and colleagues (1999) first described the ability of
ADAM10 to act as an α-secretase. Furthermore, a report by Lopez-Perez and colleagues
(2001) implicates ADAM10 as a contributor to constitutive sAPP-α production, while
others have described it as acting in more of a regulative capacity (Skovronsky et al.,
2000). Interestingly, in cerebrospinal fluid from AD patients, ADAM10 and
corresponding sAPP-α/α-CTFs are decreased, suggesting that non-amyloidogenic/αsecretase APP proteolysis is impaired in AD patients (Lannfelt et al., 1995; Sennvik et
al., 2000; Colciaghi et al., 2004). ADAM10 activity is also decreased in AD and Down’s
syndrome brains (Bernstein et al., 2003). Moreover, a recent study shows that a moderate
neuronal overexpression of ADAM10 in mice transgenic for human APP([V717I])
increased the secretion of the neurotrophic soluble sAPP-α, reduced the formation of Aβ
peptides, and prevented their deposition as plaques (Postina et al., 2004). Previous
studies have also shown that enhanced ADAM10 activity prevented cognitive impairment
in a mouse model of AD. Although the individual contributions of the putative αsecretases to the AD process still remain unclear, the above mentioned studies raise the
possibility that a strategy of increasing α-secretase activity may provide a promising
therapeutic target for AD.

3.1.2 Proprotein convertases (PC)
Conversion of N-glycosylated zymogen/pro-form of ADAM10 into its mature
form by proprotein convertases (PCs) is required for its activation and protease activity in
α-secretase APP cleavage (Anders et al., 2001; Camden et al., 2005; Anders et al., 2006).
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In a recent study by Hwang and colleagues (2006), the PC furin was identified as a key
regulator of ADAM10 mediated α-secretase APP cleavage. Other previous reports not
only suggest the role of furin, but also that of prohormone convertase-7 (PC7) in
ADAM10 activation (Anders et al., 2001; Lopez-Perez et al., 2001). While the identity
of the PC responsible for ADAM10 maturation is uncertain, there also remains a debate
over the cellular location of its activation between the trans-Golgi network (TGN) and the
plasma membrane. In view of this, it may be important to clarify the degree of surface or
TGN ADAM10 maturation and its signaling mechanism.

3.1.3 Phosphoinositide-3 kinase (PI3K)
Several intracellular signaling pathways have been implicated in the actions of
EGCG. In particular, the phosphoinositide-3 kinase (PI3K)/AKT signaling pathway have
been reported to play a role in the action of EGCG. PI3K consists of a heterodimer, with
separate regulatory and catalytic subunits. The most common regulatory subunit is p85
(Terauchi et al., 1999). Following phosphorylation of src-homology (SH) domains on
target proteins, p85 docks the PI3K dimer to propagate the signaling cascade (Shepherd
et al., 1998). PI3K signaling in EGCG-mediated mechanisms has largely been explored
in non-neuronal tissue. For instance, topical EGCG induces proliferation of normal
human keratinocytes via ERK1/2 and AKT (Chung et al., 2003). A rapid activation of
endothelial nitric oxide synthase involving PI3K, PKA and AKT after EGCG treatment
has also been demonstrated (Lorenz et. al, 2004). However, in a study by Petanceska and
Gandy (1999) PI3K was implicated for its role in regulating the release of sAPP-α from
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SweAPP N2a cells, mainly by affecting vesicular trafficking. Accordingly, PI3K may
yet play another role in APP metabolism.

3.2 Materials and methods

3.2.1 Reagents
Green tea-derived flavonoids (>95% purity by HPLC), including EGCG, (-)epicatechin [(-) EC], (+)-epicatechin [(+) EC], (-)-gallocatechin (GC), and (-)-catechin
(C) were purchased from Sigma (St. Louis, MO, USA). TNF-α protease inhibitor-1
(TAPI-1) and wortmannin were obtained from Calbiochem (San Diego, CA, USA).
Green tea extract (75% polyphenols) was obtained from the Vitamin Shoppe (North
Bergen, NJ, USA). carboxyl-terminal antibody APP 369 (1:1000; kindly provided by S.
Gandy and H. Steiner), carboxyl-terminal APP antibody (1:500; Calbiochem, Temecula,
CA, USA), amino-terminal APP antibody (1:1000, 22C11; Roche, Basel, Switzerland),
amino-terminal Aβ antibodies BAM-10 (1:1000; Sigma) and 6E10 (1:1000; Signet
Laboratories, Dedham, MA, USA), ADAM9 antibody (1:1000; Sigma), ADAM10
antibodies (1:1000; Calbiochem and Chemicon), TNF-α converting enzyme
(TACE)/ADAM17 antibodies (1:1000; Calbiochem and Sigma), phospho-Tyr p85 PI3K
binding motif antibody (1:1000; Cell Signaling Technology, Danvers, MA, USA), Furin
antibody (1:1000; Biomol International, Plymouth Meeting, PA, USA), PC7 antibody
(1:1000; Abcam, Cambridge, MA, USA), tau antibodies (AT270 and AT8, 1:1000;
Innogenetics, Alpharetta, GA, USA) or actin antibody (1:1500; as an internal reference
control; Roche) were employed for western blot analysis as described in section 2.4.
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3.2.2 Mice
For intraperitoneal administration of EGCG, a total of 10 female APPsw mice
from a mixed background of 56.25% C57, 12.5% B6, 18.75% SJL, and 12.5% SwissWebster were used. Beginning at 12 months of age, these mice were intraperitoneally
injected with EGCG (20 mg/kg; n = 5) or PBS vehicle (n = 5) daily for 60 days.
Similarly-aged non-transgenic (NT) mice (n = 5) were concurrently given daily
intraperitoneal injections of PBS as well. All mice were then sacrificed at 14 months of
age for analyses of Aβ levels and plaque burdens according to methods described in
sections 2.3 and 2.10. For intracerebroventricular injection of EGCG, a total of 6 female
APPsw mice from a B6/SJL background were used. At 12 months of age these mice were
intracerebroventricularlly injected with EGCG (0.5 mg/kg; n = 3) or PBS vehicle (n = 3)
once as described in section 2.2. 24 hours after injection, these mice were sacrificed for
analysis of cerebral Aβ levels as described in section 2.3 and 2.10. For oral
administration (water bottle) of EGCG, a total of 20 female APPsw mice from a B6/SJL
background were used. Beginning at 8 months of age, these mice were administered
EGCG (50 mg/kg) in H2O daily for 6 months (n = 10) or H2O alone (n = 10). Similarlyaged NT mice (n = 8) also received H2O alone. All mice were then sacrificed at
14 months of age for analyses of Aβ levels and plaque burdens as described in section 2.3
and 2.10. All behavioral testing for intraperitoneal and oral studies occurred during the
final weeks proceeding sacrifice, with treatment being continued, as described in section
2.14.
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3.3 Results

3.3.1 EGCG inhibits Aβ1–40,42 generation from SweAPP N2a cells and Tg APPsw
mouse-derived primary neuronal cells
HPLC analysis of green tea shows that EGCG is the main polyphenolic
constituent, although other compounds, including (-) EC, (+) EC, GC, and C, are present
in relatively lesser quantities (Moyers and Kumar, 2004). To examine the effects of the
polyphenolic constituents of green tea on APP metabolism, SweAPP N2a cells and
primary neuronal cells derived from Tg APPsw mice were first treated with a wide
concentration range of each of these compounds for 12 hours and cultured media was
subjected to ELISA analysis. As shown in Figure 3.1a and b, EGCG significantly
reduced Aβ1–40,42 generation in both SweAPP N2a cells and primary Tg APPsw-derived
neuronal cells in a concentration dependent manner. Importantly, EGCG (20 µM)
reduced Aβ generation by 61% and 38% in SweAPP N2a cells and primary Tg APPswderived neuronal cells by 38%, respectively (Figure 3.1a,b). It should be noted that both
enantiomeric species of another green tea component, EC, inhibited Aβ generation by
nearly 20–30% in both cell types, albeit at relatively high doses (Figure 3.1a,b).
However, two other components of green tea, GC and C, modestly promoted Aβ
production by ~20–30% and 10–15% in SweAPP N2a cells and primary Tg APPswderived neuronal cells, respectively, at relatively high (80 µM) concentrations. To
determine whether GC and/or C could oppose the inhibition of Aβ generation mediated
by EGCG, SweAPP N2a cells were co-treated with EGCG (20 µM) and GC (80 µM), C
(80 µM), or both for 12 hours and cultured media was subjected to ELISA analysis. As
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Figure 3.1
EGCG treatment inhibts Aβ generation in cultured neuronal cells. Aβ1–40,42 peptides were
analyzed in cultured media from SweAPP N2a cells (a, c, d) or TgAPPsw mouse-derived
primary neuronal cells (b) by ELISA (n = 3 for each condition). Data are represented as a
percentage of Aβ1–40,42 peptides secreted 12 hours after EGCG treatment relative to
control (untreated). a, b, One-way ANOVA followed by post hoc comparison revealed
significant differences between EGCG and the other compounds at 40, 20, 10, and 5 µM
treatment concentrations (p < 0.001). c, When comparing EGCG (20 µM) treatment with
cotreatment of SweAPP N2a cells with EGCG (20 µM) plus GC (80 µM), C (80 µM), or
GC/C, a significant difference was noted for each comparison (p < 0.001). d, SweAPP
N2a cells were treated with EGCG at a comparable concentration with that found in GT
(GT contains 30% EGCG), and a significant difference was noted between GT and
EGCG treatments (40 µg/ml vs 20 µM; 20 µg/ml vs 10 µM; 10 µg/ml vs 5 µM) on
inhibition of Aβ generation (p < 0.001 for each comparison). Reduction for each
treatment condition is indicated for c and d.
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expected, data show that the presence of GC or C, and particularly the combination of
both, markedly inhibited the ability of EGCG to reduce Aβ generation from SweAPP
N2a cells (Figure 3.1c). Thus, these data suggest that a purified preparation of EGCG
may be more capable of reducing Aβ generation in vitro than when it is present in a
mixture of whole green tea extract (GT). To further address this hypothesis, SweAPP
N2a cells were incubated with various concentrations of EGCG alone and equivalent
concentrations of EGCG that were contained in a mixture of GT in parallel. As shown in
Figure 3.1d, data indicate that the various concentrations of EGCG alone elicited more
profound effects on Aβ generation versus that contained in GT. Accordingly, the ability
of the purified EGCG alone to inhibit Aβ generation appears to be much greater than that
of GT.

3.3.2 EGCG activates non-amyloidogenic proteolysis of APP in SweAPP N2a cells
To elucidate the potential mechanism whereby green tea components modulate
APP metabolism, SweAPP N2a cells were treated with a wide concentration range of
EGCG, EC, GC, and C for 12 hours. Following western blot and immunoprecipitation
analysis, lysates of EGCG treated cells evidenced significantly increased α-CTF
generation and augmented α-CTF to β-CTF band density ratios (Figure 3.2a). In
addition, these effects were appeared to be both time and concentration dependent (Figure
3.2c,d). In concert with these findings, sAPP-α, but not sAPP-β, was elevated in cultured
media from EGCG treated (20 µM) SweAPP N2a cells (Figure 3.2b). Additionally, as
shown in Figure 3.2e (-) EC treatment only increased α-CTF
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Figure 3.2a-d
EGCG treatment modulates APP metabolism in vitro. a, b, SweAPP N2 a cells were
treated with EGCG at 20 µM or PBS (control) for 12 hours. a, Cell lysates were prepared
and subjected to western blot (WB) analysis of APP CTFs, and b, cultured media were
collected for immunoprecipitation (IP)/WB. c, d, Cell lysates were prepared from
SweAPP N2a cells treated with EGCG at 20µM for times indicated (c) or concentrations
indicated for 12 hours (d) and subjected to WB for APP CTFs. b, WB analysis using
antibody 22C11 against the amino-terminus of APP shows sAPP-α (IP with antibody
6E10) and sAPP-β [following immunodepletion (ID) with 6E10 and subsequent IP with
22C11]. a, c, d, Densitometric analysis of the ratio of α-CTF to β-CTF are indicated
below the figures. a, A t test revealed a significant difference between EGCG treatment
and control (n = 3 for each condition; p < 0.001).
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Figure 3.2e-g
Green tea flavonoids modulate APP metabolism in vitro. e, g, SweAPP N2a cells were
treated with EGCG (-) EC, (+) EC, GC, C, or GT at concentrations indicated for 12
hours. f, SweAPP N2a cells were co-treated with EGCG (20 µM) and GC, C, or GC/C at
80 µM for 12 hours. e, f, g, Lysates were subjected to western blot (WB) analysis of
APP CTFs. f, g, Densitometric analysis of the ratio of α-CTF to β-CTF are indicated
below the figures. f, One-way ANOVA followed by post hoc comparison revealed
significant between-groups differences (p < 0.01) with n = 4 for each condition, and t test
revealed a significant difference between EGCG and EGCG/GC/C treatments (p <
0.001).
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generation at a concentration of 80 µM (similar results were obtained with (+) EC; data
not shown). Conversely, both GC and C treatment resulted in decreased α-CTF to β-CTF
ratios at 80µM concentrations (Figure 3.2e). Interestingly, at this concentration, GC, C,
or a GC/C combination significantly opposed the effect of EGCG (20 µM) on α-CTF
generation (Figure 3.2f). In agreement with Aβ ELISA data as shown in Figure 3.1d,
purified EGCG demonstrated a markedly superior effect on α-CTF generation versus
equivalent amounts present in GT (Figure 2g). Taking into consideration the lack of any
observable changes in full length holo APP expression after treatment, it is apparent that
EGCG promoted α-CTF generation and sAPP-α release at the post-translational level,
events which are indicative of non-amyloidogenic APP proteolysis.

3.3.3 EGCG promotes α-secretase activity in SweAPP N2a cells
As illustrated in Figure 3.2c, western blot analysis clearly shows a time dependent
increase in α-CTF generation in EGCG-treated SweAPP N2a cells. Notably, α-CTF
generation increased at ~3–4 hours through 8 hours after EGCG treatment. To confirm
that the observed alterations in APP metabolism were attributable to enhanced α-secretase
activity, the expression of TACE/ADAM17, an α-secretase candidate (Skovronsky et al.,
2001; Allinson et al., 2003), was examined in SweAPP N2a cells following EGCG
treatment. Western blot analysis of lysates revealed significant increases in
TACE/ADAM17 expression ~2–4 hours after EGCG treatment, which was then rapidly
degraded through 8 hours (Figure 3.3a). To evaluate whether this EGCG-mediated
alteration in TACE expression correlated with α-secretase activity, we evaluated α, β, and
γ-secretase activity in cell lysates prepared from EGCG treated SweAPP N2a cells
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Figure 3.3a and b
EGCG treatment promotes α-secretase activity in vitro. a, b, Cell lysates were prepared
from SweAPP N2a cells treated with EGCG (20µM) for different time points as
indicated. a, Western blot analysis by anti-TACE antibody shows TACE/ADAM17 and
cleaved fragments. b, α-, β -, and γ-secretase activities were analyzed in cell lysates using
secretase activity assay. Data are presented as a percentage of fluorescence
units/milligrams protein activated 1, 2, or 3 hours after EGCG treatment relative to
control (PBS). A t test revealed a significant difference between α-secretase and either βor γ-secretase cleavage activity at 1, 2, and 3 hours after EGCG treatment (p < 0.001)
with n = 3 for each condition.
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Figure 3.3c-e
EGCG effects are attenuated by an inhibitor of a putative α-secretase in vitro. c–e,
SweAPP N2a cells were treated with EGCG (20 µM) or PBS (control) in the presence or
absence of TAPI-1 at various concentrations (c) or at 25 µM (d, e) for 4 hours. Cell
cultured supernatants were collected, and cell lysates were prepared from cultured cells.
c, Lysates were subjected to western blot analysis of APP CTFs. d, Data are represented
as percentage of α-secretase activity calculated in terms of fluorescence units/milligrams
protein. A t test revealed a significant difference between EGCG treatment and cotreatment with EGCG and TAPI-1 (p < 0.001); increased levels of activity are indicated.
e, Data are presented as percentage of Aβ secretion relative to PBS control 4 hours after
EGCG treatment in the presence or absence of TAPI-1. A t test revealed a significant
difference between EGCG and EGCG/TAPI-1 treatment (p < 0.001); reduction for each
treatment condition (n = 3) is indicated.
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by fluorometic assay. As indicated by Figure 3.3b, only α-secretase activity was
significantly elevated during the first 3 hours following EGCG treatment of SweAPP N2a
cells. To further confirm this putative α-secretase role in this mechanism, SweAPP N2a
cells were co-treated with EGCG and the TACE/ADAM17 inhibitor TAPI-1 (Slack et al.,
2001) for 4 hours. Following western blot and ELISA analysis, lysates and media from
TAPI-1 co-treated cells evidenced both significantly diminished α-secretase activity and
α-CTF generation (Figure 3.3c,d). Consistent with these findings, EGCG-mediated
reductions of soluble Aβ were also decreased by half (Figure 3.3e). Together, these data
suggest that elevation of TACE/ADAM17 activation in response to EGCG treatment may
be partly responsible for increased α-secretase activity in SweAPP N2a cells.

3.3.4 EGCG treatment enhances ADAM10 activation in cultured CNS cells
To determine whether EGCG invariably modulates the expression of all of the
potential candidate α-secretases (ADAM9, -10, or -17), SweAPP N2a cells were treated
with various concentrations of EGCG for 8 hours and lysates were subjected to western
blot analysis. Interestingly, mature ADAM10 ( 60 kDa isoform), but not ADAM9 or
TACE/ADAM17, concentration dependently increased in response to EGCG treatment
(Figure 3.4a). To investigate if EGCG treatment may affect mRNA expression of
ADAM10 across the time frame examined above, total RNA from cells treated in parallel
was isolated for RT-PCR analysis. However, no significant differences in ADAM10
mRNA levels between EGCG concentrations were detectable (Figure 3.4b). Temporal
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Figure 3.4a
EGCG enhances ADAM10 activation in SweAPP N2a cells. Expression of ADAM9, 10, and -17 was analyzed in cell lysates from SweAPP N2a cells treated with EGCG at
the various concentrations indicated for 8 hours by western blot. Densitometric analysis
reveals the band density ratio of the mature (mADAM10) to the pro (pro-ADAM10) form
of ADAM10 or the band density ratio of ADAM9 or -17 to actin as indicated in panels to
the right. One-way ANOVA revealed significant differences between EGCG-treated cells
and control cultures on the ratio of mADAM10 to pro-ADAM10 (**, p < 0.001; *, p <
0.05), but no significant differences were noted for the ratios of ADAM9 or -17 to Actin
(p > 0.05) with n = 3 for each condition.
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Figure 3.4b
EGCG does not alter ADAM10 mRNA levels in SweAPP N2a cells. ADAM10 mRNA
level was analyzed in SweAPP N2a cells treated with EGCG at the various doses
indicated for 8 hours by RT-PCR. Densitometric analysis reveals the band density ratio
of ADAM10 to γ-actin as indicated below. One-way ANOVA revealed no significant
differences between EGCG treated cells and control cultures on the ratio of ADAM10 to
γ-actin (p > 0.05) with n = 2 for each condition.
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Figure 3.4c
EGCG enhances ADAM10 maturation in SweAPP N2a cells. Cell lysates were prepared
from SweAPP N2a cells treated with EGCG (20 µM) for 0, 30, 60, or 120 minutes and
subjected to western blot for ADAM10. Densitometric analysis reveals the band density
ratios of pro-ADAM10 to actin and mADAM10 to Actin as indicated in the panels to the
right. One-way ANOVA revealed significant time point differences (**, p < 0.001; *, p
< 0.05) with n = 3 for each condition.
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analysis showed significant increases in mature ADAM10 as early as 30 minutes
following treatment with EGCG (20 µM) (Figure 3.4c), an effect that continued to
increase through to 2 hours after EGCG challenge. However, no such similar significant
effects of EGCG treatment on ADAM9 or -17 were noted (data not shown). In addition,
EGCG also concentration dependently increased ADAM10 maturation in two separate
cell types, parental (non-transfected) N2a cells and N9 microglial cells. Relative to N9
microglia, the neuron-like parental N2a cell line demonstrated increased sensitivity to
EGCG treatment (Figure 3.5a). Similar to N2a and N9 cell lines, primary murine
neuronal and microglial cultures also displayed concentration dependent increases in
mature ADAM10 in response to EGCG treatment (Figure 3.5b), with primary neurons
showing increased sensitivity to the lower concentrations (10 and 20 µM) of EGCG.

3.3.5 EGCG-mediated maturation of ADAM10 correlates with α-secretase activity
in SweAPP N2a cells
To confirm that EGCG-mediated concentration dependent increases in mature
ADAM10 result in modulation of APP metabolism, SweAPP N2a cells were treated with
various concentrations of EGCG for 8 hours. APP metabolism and ADAM10 maturation
were then analyzed in parallel. Western blot analysis of lysates and cultured media
revealed concentration dependent increases in α-CTF generation and sAPP-α release with
corresponding increases in mature ADAM10 in response to EGCG treatment (Figure
3.6a-c). In concert with these findings, concentration dependent reductions in Aβ1–40 and
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Figure 3.5a
EGCG treatment enhances ADAM10 activation in both N2a and N9 cells. Cell lysates
were prepared from N2a cells or N9 microglial cells that were treated with EGCG at
various concentrations indicated for 8 hours and subjected to western blot for ADAM10.
Densitometric analysis reveals the band density ratio of mADAM10 to pro-ADAM10 as
indicated below. One-way ANOVA followed by post hoc analysis revealed significant
differences between N2a and N9 cells treated with EGCG at 10 and 20 µM (**, p <
0.001) with n = 3 for each condition.
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Figure 3.5b
EGCG treatment enhances ADAM10 activation in both cultured primary neuronal and
microglial cells. Cell lysates were prepared wild-type mouse-derived primary neuronal
or microglial cells that were treated with EGCG at various concentrations indicated for 8
hours and subjected to western blot for ADAM10. Densitometric analysis reveals the
band density ratio of mADAM10 to pro-ADAM10 as indicated below. One-way
ANOVA followed by post hoc analysis revealed significant differences between primary
neuronal and microglial cells treated with EGCG at 10 and 20 µM (**, p < 0.001) with n
= 3 for each condition.
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Figure 3.6a-d
EGCG-mediated maturation of ADAM10 correlates with α-secretase activity in SweAPP
N2a cells. SweAPP N2a cells were treated with EGCG at concentrations indicated for 8
hours. a, b, Lysates were subject to western blot for APP CTFs and ADAM10. c, d, Cell
cultured media was subjected to western blot for sAPP-α or ELISA for Aβ. As indicated
in panels to the right, densitometry analysis shows the band density ratio of α-CTF to
full-length APP (holo APP) (a) or mADAM10 to pro-ADAM10 (b). One-way ANOVA
revealed significant EGCG concentration differences on both ratios of α-CTF to holoAPP and mADAM10 to pro-ADAM10 (**, p < 0.001) with n = 3 for each condition. c,
d, Data are represented as % change relative to control (medium from cultured SweAPP
N2a cells without any treatment). One-way ANOVA revealed significant EGCG dose
differences in both ratios of sAPP-α to Actin (**, p < 0.001) and reduction of Aβ1–40 and
Aβ1–42 (*, p < 0.05; **, p < 0.001) with n = 3 for each condition.
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Figure 3.6e-h
EGCG-mediated maturation of ADAM10 correlates with α-secretase activity Tg APPsw
primary neuronal cells. Tg APPsw mouse-derived primary neuronal cells were treated
with EGCG at concentrations indicated for 8 hours. e, f, Lysates were subject to western
blot for APP CTFs and ADAM10. g, h, Cell cultured media was subjected to western
blot for sAPP-α or ELISA for Aβ. As indicated in panels to the right, densitometry
analysis shows the band density ratio of α-CTF to full-length APP (holo APP) (e) or
mADAM10 to pro-ADAM10 (f). One-way ANOVA revealed significant EGCG dose
differences on both ratios of α-CTF to holo-APP and mADAM10 to pro-ADAM10 (**, p
< 0.001) with n = 3 for each condition. g, h, Data are represented as % change relative to
control (medium from cultured Tg APPsw derived primary neuronal cells without any
treatment). One-way ANOVA revealed significant EGCG dose differences in both ratios
of sAPP-α to Actin (**, p < 0.001) and reduction of Aβ1–40 and Aβ1–42 (*, p < 0.05; **, p
< 0.001) with n = 3 for each condition.
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Aβ1-42 after EGCG treatment were evident (Figure 3.6d), not only confirming that EGCG
promotes non-amyloidogenic APP proteolysis, but also that this effect correlates with
increased ADAM10 maturation. Accordingly, primary Tg APPsw-derived neuronal cells
were also analyzed for changes in APP metabolism in response to EGCG treatment.
Western blot analysis again revealed EGCG-mediated the promotion of nonamyloidogenic proteolysis, as indicated by α-CTF to holo-APP ratios (Figure 3.6e).
Similar to data observed in SweAPP N2a cells, α-secretase activity positively correlated
with both mature ADAM10 levels and with secreted sAPP-α (Figure 3.6f,g) in these cells.
Importantly, these findings were again consistent with concentration dependent
reductions in Aβ levels following EGCG treatment (Figure 3.6h).

3.3.6 ADAM10 is required for EGCG-mediated non-amyloidogenic proteolysis of
APP
To directly examine whether ADAM10 α-secretase activity was required for
EGCG promotion of non-amyloidogenic proteolysis, siRNA knockdown experiments
targeting ADAM9, -10, or -17 were conducted. First, to confirm siRNA knockdown
efficiency, SweAPP N2a cells were treated with ADAM9, -10, or -17 siRNAs and
subjected to western blot analysis. As shown in Figure 3.7a-c protein expression levels of
ADAM10, -9, or -17 were significantly inhibited by respective ADAM-specific siRNAs.
In addition, to test the specificity of siRNA against ADAM10 versus ADAM9 or -17, the
expression of ADAM9 and -17 was analyzed from the cell lysates derived from siRNA
knockdown for ADAM10 by western blot. Lysates revealed that ADAM10 siRNA did
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Figure 3.7
siRNA knockdown efficiency for ADAM10, -9, or -17. Expression of ADAM10 (a), -17
(b), or -9 (c) was analyzed by western blot in cell lysates from SweAPP N2a cells
transfected with siRNA targeting ADAM10, -9, or -17 at 48 hours after transfection.
Densitometric analysis reveals the band density ratios of pro-ADAM10, ADAM17, and
ADAM9 to Actin as indicated in the panels below. One-way ANOVA revealed
significant differences between siRNA-transfected cells and control cultures on the ratio
of ADAMs to Actin (**, p > 0.001) with n = 3 for each condition. d, expression of
ADAM9 or -17 was analyzed by western blot in cell lysates from SweAPP N2a cells
transfected with siRNA targeting ADAM10 at 48 hours after transfection. Densitometric
analysis reveals the band density ratios of pro-ADAM17 to Actin or ADAM10 to Actin
as indicated in the panel below. A t test revealed no significant differences between
siRNA-transfected cells and control cultures on the ratio of ADAM9 or ADAM17 to
Actin (p > 0.05) with n = 3 for each condition.
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Figure 3.8a
ADAM10 is required for EGCG-mediated non-amyloidogenic proteolysis of APP. Cell
lysates were prepared and collected from SweAPP N2a cells transfected with ADAM9, 10, or -17 siRNA or non-targeting siRNA control (siRNA control) for 48 hous and then
treated with EGCG (20 µM) for 8 hours. Cell lysates were subjected to western blot for
APP CTFs and ADAM10. Densitometric analysis reveals the band density ratios of αCTF to holo-APP (upper right panel), pro-ADAM10 to Actin (middle right panel), or
mADAM10 to Actin (lower right panel) as indicated. A t test revealed a significant
difference between ADAM10 siRNA and ADAM9 or ADAM17 siRNA or siRNA
control (**, p < 0.001) on the ratios of α-CTF to holo-APP, pro-ADAM10 to Actin, or
mADAM10 to Actin with n = 3 for each condition.
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Figure 3.8b and c
ADAM10 is required for EGCG-mediated non-amyloidogenic proteolysis of APP and
reduction of Aβ generation. b, c, conditioned media were prepared and collected from
SweAPP N2a cells transfected with ADAM9, -10, or -17 siRNA or non-targeting siRNA
control (siRNA control) for 48 h and then treated with EGCG (20 µM) for 8 hours. Cell
cultured media were subjected to western blot for sAPP-α release (b) or ELISA for Aβ
(c). Densitometric analysis reveals the band density ratios of sAPP-α to Actin as
indicated below. A t test revealed a significant difference between ADAM10 siRNA and
ADAM9 or ADAM17 siRNA or siRNA control (**, p < 0.001) on the reduction of
sAPP-α and Aβ species as indicated with n = 3 for each condition.
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not alter the expression of ADAM9 or -17 (Figure 3.7d). Subsequently, α-CTF
production in APPsw N2a cells subjected to siRNA knockdown of ADAMs following
treatment with EGCG (20 µM) was analyzed by western blot. As illustrated by Figure
3.8a and b, only ADAM10 siRNA was able to both clearly inhibit the expression of
ADAM10 and block EGCG-induced α-CTF generation and sAPP-α release. This effect
of ADAM10 siRNA on blocking EGCG-induced non-amyloidogenic APP proteolysis
was further borne out by ELISA analysis, where only ADAM10 siRNA attenuated
EGCG-induced reduction of Aβ 1–40 and Aβ 1–42 (Figure 3.8c). Taken together, these data
demonstrate the requirement of ADAM10 for EGCG-mediated promotion of nonamyloidogenic proteolysis of APP

3.3.7 PI3K signaling is involved in EGCG-mediated α-secretase activity.
To further establish the mechanism whereby EGCG promotes ADAM10
maturation and non-amyloidogenic proteolysis of APP, a variety of signaling proteins and
second messenger systems were investigated for their potential importance. SweAPP
N2a cells were first co-treated with various signaling inhibitors in the presence of 20 µM
EGCG for 12 hours and cultured media was subjected to ELISA analysis. In the context
of EGCG (20 µM), the PI3K inhibitor wortmannin concentration dependently reduced
sAPP-α release with an estimated IC50 of 20 µM (Figure 3.9a). To confirm this inhibition
of EGCG-mediated non-amyloidogenic proteolysis, SweAPP N2a cells were again cotreated with a range of concentrations of wortamanin in presence of EGCG for 8
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Figure 3.9a-c
PI3K signaling is involved in EGCG-mediated α-secretase activity. a, Levels of sAPP-α
release were analyzed in cultured media from SweAPP N2a cells treated with EGCG (20
µM) in the presence of a PI3K inhibitor (wortmannin) at concentrations indicated for 12
hour by ELISA. b,c, ADAM10 expression was analyzed in lysates from SweAPP N2a
cells treated with EGCG (20 µM) in the presence of a PI3K inhibitor (wortmannin) at
concentrations indicated for 8 hours by western blot. c, Densitometric analysis shows the
band density ratio of the mature (mADAM10) to the pro (pro-ADAM10) form of
ADAM10. One-way ANOVA followed by post hoc analysis revealed significant
differences between between wortmannin treated cells and control (**, p < 0.005) with n
= 3 for each condition.
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hours and lysates were subjected to western blot analysis. As expected, wortmannin
treatment significantly inhibited EGCG-mediated ADAM10 maturation (Figure 3.9b,c).
As depicted in Figure 3.9a-c, a concentration dependent trend is noticeable, even though
there is obvious cellular toxicity following co-treatment at concentrations of 100 µM.
Importantly, given the lack of any detectable cytotoxicity of wortmannin at
concentrations below 100 µM (by protein levels and LDH release; data not shown), it
may be fair to conclude that these effects are not mediated by cell death. Interestingly,
following western blot analysis of lysates from SweAPP N2a cells treated with a range of
concentrations of EGCG, a significant increase in phosphorylated p85 binding motifs on
a high molecular weight species (~100 kDa) is evident (Figure 3.9e,d). Therefore, when
considering the above data, it is apparent that ADAM10 maturation involves or even is
potentially dependent upon PI3K signaling.

3.3.8 EGCG treatment enhances furin activation in SweAPP N2a cells
To determine whether EGCG modulates expression of potential proprotein
convertases upstream of ADAM10, APPsw N2a cells were treated with various
concentrations of EGCG for 4 hours and lysates were subjected to western blot analysis.
Expression of furin, but neither isoform of PC7, concentration dependently increased in
response to EGCG treatment (Figure 3.10a-d). Notably, both the pro-form (~108 kDa)
and mature (~96 kDa) form of furin significantly increase, which suggests that EGCG
may be acting at the level of transcription. However, to rule out the role of PI3K in the
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Figure 3.9d and e
EGCG enhances PI3K signaling in SweAPP N2a cells. d, Expression of phosphorylated
p85 binding motifs was analyzed in lysates from SweAPP N2a cells treated with EGCG
at concentrations indicated for 4 hours by western blot. e, Densitometric analysis reveals
the band density ratio of p85 binding motifs to Actin. One-way ANOVA followed by
post hoc analysis revealed significant differences between EGCG treatments and control
(*, p < 0.05; **, p < 0.005) with n = 3 for each condition.
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Figure 3.10a-d
EGCG treatment enhances furin activation in SweAPP N2a cells. a, b, Expression of
furin and PC7 was analyzed in lysates from SweAPP N2a cells treated with EGCG at
concentrations indicated for 4 hours by western blot. c, d, Densitometric analysis reveals
the band density ratio of furin or PC7 isoforms to Actin. One-way ANOVA revealed
significant differences between each EGCG concentration in ratios of furin to Actin (p <
0.01) with n = 3 for each condition.
.

60

Figure 3.10e and f
PI3K inhibition does not affect EGCG-mediated furin activation in SweAPP N2a cells.
e, Expression of furin was analyzed in lysates from SweAPP N2a cells treated with
EGCG (20 µM) in the presence of a PI3K inhibitor (wortmannin) at concentrations
indicated at concentrations indicated for 4 hours by western blot. f, Densitometric
analysis reveals the band density ratio of furin or to Actin.
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EGCG-mediated maturation of furin, SweAPP N2a cells were co-treated with a range of
concentrations of the PI3K inhibitor wortamanin in presence of EGCG (20 µM) for 4
hours and lysates were subjected to western blot analysis. As illustrated by Figure 3.10 e
and f, wortmannin treatment did not significantly affect furin expression in the context of
EGCG. This phenomenon not only suggests that EGCG’s signaling mechanism may
branch, but also suggests that PI3K may be acting at the level of ADAM10 maturation.

3.3.9 EGCG treatment reduces Aβ pathology and promotes non-amyloidogenic
proteolysis of APP in Tg APPsw mice
To validate in vivo whether EGCG treatment could modulate APP metabolism
and impact cerebral Aβ levels/plaque burden in Alzheimer transgenic mice we
intraperitoneally administered EGCG to Tg APPsw mice, a well-established transgenic
mouse model of AD, at an age when Aβ deposits had begun to form (12 months). EGCG
was administered based on a treatment schedule that produced benefit in an
atherosclerosis mouse model (Chyu et al., 2004). At 12 months of age, Tg APPsw mice
were intraperitoneally injected with EGCG (20 mg/kg) or PBS daily for 60 days.
Following treatment, ELISA analysis of brain homogenates revealed that both soluble
Aβ1-40 and Aβ1-42 levels were reduced by 54% and 44%, respectively, in EGCG-treated Tg
APPsw mice. Insoluble Aβ1–40 and Aβ1-42 levels were also reduced by 47% and 38%,
respectively, in EGCG-treated Tg APPsw mice, as determined by ELISA of brain
homogenates (Figure 3.11b,c). Consistent with these findings, analysis of plaque burden
by 4G8 immunohistochemistry and thioflavin S staining from coronally sectioned brains
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Figure 3.11a-d
EGCG treatment reduces Aβ pathology and promotes non-amyloidogenic proteolysis of
APP in Tg APPsw mice. Brain homogenates were prepared from female Tg APPsw mice
treated with EGCG (n = 5) or PBS (n = 5). a, Top panel, western blot analysis by
antibody 369 shows holo APP and two bands corresponding to β-CTF and α-CTF. a,
Middle and bottom panels, western blot analysis by antibody 22C11 shows holo-APP
(middle; following ID/carboxyl-terminal APP antibody) and sAPP-α (bottom; following
ID/C-terminal APP antibody and IP/6E10). Detergent-soluble Aβ1–40,42 (b) and insoluble
Aβ1–40,42 prepared with 5 M guanidine (c) were analyzed by ELISA. Data are presented
as mean ± 1 SEM of Aβ1–40 or Aβ1–42 (pg/mg protein) separately. b, c, A t test revealed a
significant between-groups difference for either soluble or insoluble Aβ1–40,42 (p < 0.001
for each comparison). d, α-, β-, and γ-secretase cleavage activities were analyzed by
secretase cleavage activity assays. Data are presented as mean ± 1 SEM of fluorescence
units/mg protein. A t test revealed a significant difference between EGCG- and PBStreated Tg APPsw mice for α-secretase activity (p < 0.001).
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Figure 3.11e and f
EGCG treatment reduces Aβ pathology in Tg APPsw mice. e, Mouse brain coronal
paraffin sections were stained with anti-human Aβ antibody (4G8). Left, Control PBS
treated mice (n = 5). Right, EGCG treated mice (n = 5). The top panels are from the
cingulate cortex (CC), the middle panels are from the hippocampus (H), and the bottom
panels are from the entorhinal cortex (EC). f, Percentages of 4G8-immunoreactive Aβ
plaques (mean ± 1 SEM) were calculated by quantitative image analysis, and reduction
for each brain region is indicated. A t test for independent samples revealed significant
differences (p < 0.005) between groups for each brain region examined. Scale bar, 50
µm.
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Figure 3.11g and h
EGCG treatment reduces Aβ pathology in Tg APPsw mice. g, Mouse brain sections from
the indicated brain regions were stained with thioflavin S. Left, Control PBS treated
mice (n = 5). Right, EGCG treated mice (n = 5). h, Percentage of thioflavin S plaques
(mean ± 1 SEM) were quantified by image analysis, and reduction for each brain region
is indicated. A t test for independent samples revealed significant differences (p < 0.005)
between groups for each brain region examined. Scale bar, 50 µm.
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of EGCG treated Tg APPsw mice showed 47–54% (Figure 3.11f) and 35–46% (Figure
3.11h) reductions in amyloid pathology across hippocampal and cortical brain regions,
respectively. In addition, non-amyloidogenic APP fragments, including α-CTF and
sAPP-α, were markedly increased in brain homogenates of Tg APPsw mice treated with
EGCG versus vehicle, as determined by western blot (Figure 3.11a). Fluorometric assay
analysis also revealed a 40% increase in α-secretase activity in treatment animals (Figure
3.11d). Taken together, the above data suggest that EGCG may act as an α-secretase
agonist in this transgenic mouse model of AD.
However, due to route of administration, it was unclear as to whether these
EGCG-mediated effects were attributable to action of the compound in the periphery
and/or the CNS. To answer this question, EGCG was administered
intracerebroventricularly (0.5 mg/kg) to Tg APPsw mice. Following 24 hours treatment,
brain homogenates of Tg APPsw mice showed significant reductions in cerebral soluble
Aβ1–40,42 levels by 39%, an effect that was associated with increased α-CTF generation,
sAPP-α release, α-secretase activity (data not shown). Importantly, cerebral soluble Aβ1–
40,42 levels

were reduced by a comparable magnitude as was evidenced in

intraperitoneally injected Tg APPsw mice, further indicating that the in vivo effects of
EGCG are mainly owed to the action of this compound CNS. Together, the above lines
of evidence confirm that EGCG promotes non-amyloidogenic proteolysis of APP and
attenuates cerebral amyloidosis in this transgenic mouse model of AD.
To determine whether oral administration of EGCG could have similar antiamyloidogenic effects using a theoretically equivalent dose to that used in the previous
intraperitoneally administered EGCG study, Tg APPsw mice were orally treated with
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EGCG or vehicle (H2O) starting at 8 months of age for 6 months. As shown in Figure
3.12a and c, EGCG treatment (50 mg/kg as determined by recorded daily intake and
HPLC) similarly reduced cerebral amyloidosis in these mice. Image analysis of
micrographs from Aβ antibody stained coronal sections revealed that plaque burdens
were significantly reduced in the cingulate cortex, hippocampus, and entorhinal cortex by
54%, 43%, and 51%, respectively (Figure 3.12b). Furthermore, Congo red plaque
burdens decreased significantly by 53%, 53%, and 58% respectively as well (Figure
3.12d). To verify the findings from these coronal sections, we analyzed anterior quarter
brain homogenates for Aβ levels by ELISA. Again, EGCG oral treatment markedly
decreased both soluble and insoluble forms of Aβ1–40, 42 (Figure 3.13a,b). As expected,
EGCG treatment significantly increased ADAM10 maturation and resulted in an
approximately 2-fold elevation in sAPP-α release, as determined by western blot and
ELISA analysis (Figure 3.13c,d). Taken together, the above data confirm an oral route of
administration provides effective attenuation of amyloid pathology comparable to that of
intraperitoneally administered EGCG.

3.3.10 EGCG treatment modulates tau hyperphosphorylation in Tg APPsw mice

To investigate the possibility that EGCG treatment may also affect tau
physiology, brain homogenates from the intraperitoneally injected EGCG (20 mg/kg)
treatment groups were analyzed by western blot. Figure 3.14 represents soluble and
insoluble fractions of phosphorylated tau detected in the homogenates of the treatment
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Figure 3.12a and b
Oral administration of EGCG reduces Aβ pathology in Tg APPsw mice. a, Mouse brain
coronal frozen sections were stained with rabbit polyclonal anti-human Aβ antibody.
Left, EGCG treated Tg mice. Right, Control Tg mice. The top panels are from the
cingulated cortex (CC), the middle panels are from the hippocampus (H), and bottom
panels are from the entorhinal cortex (EC). b, Percentages of Aβ antibodyimmunoreactive Aβ plaque (mean ± SEM) were calculated by quantitative image
analysis. A t test for independent samples revealed significant differences (n = 10 for
each condition; *p< 0.05; **p < 0.001) between groups for each brain region examined.
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Figure 3.12c and d
Oral administration of EGCG reduces Aβ pathology in Tg APPsw mice. c, Mouse brain
coronal frozen sections were stained with Congo red. Left, EGCG treated Tg mice. Right,
Control Tg mice. The top panels are from the cingulated cortex (CC), the middle panels
are from the hippocampus (H), and bottom panels are from the entorhinal cortex (EC). d,
Percentage of Congo red plaques (mean ± SEM) were quantified by image analysis. A t
test for independent samples revealed significant differences (n = 10 for each condition;
*p < 0.005; **p < 0.001) between groups for each brain region examined.
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Figure 3.13
Oral administration of EGCG reduces both soluble and insoluble Aβ1–-40, 42 levels by nonamyloidogenic APP proteolysis. Brain homogenates were prepared from Tg APPsw mice
treated with EGCG or H2O. Soluble Aβ1–40, 42 (a) and insoluble Soluble Aβ1–40, 42
prepared with 5 M guanidine (b) were analyzed by ELISA. Data are presented as (pg/mg
protein) of Aβ1–40 or Aβ1–42 separately. c, Densitometric analysis reveals the band density
ratio of mADAM10 to Actin indicated below. D, ELISA for sAPP-α release in brain
homogenates. Data were represented as a mean fold of sAPP-α relative to control. a, b,
A t test revealed a significant between-groups difference for either soluble or insoluble
Aβ1–40, 42 (*p < 0.005; **p < 0.001 for each comparison). Mean ± SEM for each group
(n = 10 for each condition). c, d, A t test revealed a significant between-groups
difference for sAPP-α generation (**p < 0.001). Mean ± SEM for each group (n = 5 for
each condition).
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Figure 3.14
EGCG treatment modulates tau hyperphosphorylation in Tg APPsw mice. Brain
homogenates were prepared from Tg mice treated intraperitoneally with EGCG or PBS.
a, Top, western blot analysis by antibody AT270 shows total phosphorylated tau protein.
Western blot analysis by antibody AT270 shows sarkosyl-soluble phospho-tau (a,
middle) and sarkosyl-insoluble phospho-tau (a, bottom). b, Densitometric analysis
reveals the ratios of sarkosyl-soluble phospho-tau to total soluble tau (top) and of
insoluble phospho-tau to total soluble tau (bottom). A t test revealed a significant
difference between EGCG treatment and PBS control Tg mice (**p < 0.001).
Mean ± SEM for each group (n = 5 for each condition).
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groups and their control littermates by AT270 antibody. Clearly, untreated transgenic
animals exhibit significantly higher amounts of sarkosyl-soluble (S2) phospho-tau and
lower amounts of sarkosyl-insoluble (P3) phospho-tau when compared to EGCG-treated
animals (Figure 3.14). In fact, EGCG-treated Tg APPsw mice present a phospho-tau
profile similar to that of the control littermates (NT, non-transgenics). In accordance
with expectations, oral treatment groups also presented similar phospho-tau profiles (data
not shown). Interestingly, the S2 fraction of non-treated Tg APPsw mice presents the
highest amount of A68 bands, which are supposedly indicative of the 60–68 kD
abnormally phosphorylated, neurotoxic tau species (Brion et al., 1991; Shin et al., 1993).
On the other hand, both the EGCG-treated Tg APPsw mice and control littermates have
markedly higher levels of insoluble A68 bands present in the P3 fraction compared to that
of non-treated Tg APPsw animals. Phospho-tau analysis of brain homogenates employing
AT8 antibody revealed no significant differences between treatment groups; however, it
is important to note that levels of tau pathology were quite low in comparison to AT270
(data not shown). Altogether, these findings not only suggest that the presence of Aβ
may sustain levels of neurotoxic soluble phosphorylated tau isoforms, but also suggest
that EGCG may oppose these effects.

3.3.11 EGCG provides cognitive benefit in Tg APPsw mice
To determine any potential cognitive benefits afforded by EGCG administered
either intraperitoneally or orally, working memory performance was evaluated using a
well established radial arm water maze (RAWM) task. In Tg APPsw vehicle injected
mice tested at 14 months of age, a clear working memory impairment was evident in
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comparison to NT controls (Figure 3.15a,c). By sharp contrast, Tg APPsw mice that had
been given two months of intraperitoneally injected EGCG (20 mg/kg) from 12–
14 months of age had substantiallyimproved working memory performance that was
comparable to that of NT control mice. Specifically, robust benefits of intraperitoneally
administered EGCG were evident on Trial 5 (T5) working memory performance during
the final block of RAWM testing (Figure 3.15a), as well as comparing Trial 1 (naïve
trial) to Trial 5 improvement on the final day of RAWM testing (Figure 3.15c).
Regarding the later, both NT controls and EGCG treated Tg APPsw mice showed a
marked improvement between T1 and T5, while Tg APPsw control mice showed no
working memory improvement. Moreover, the T5 working memory performance of Tg
APPsw mice treated with EGCG was dramatically better than Tg APPsw controls and
identical to NT controls during this last day of RAWM testing (Figure 3.15c).
In the other study, Tg APPsw mice were treated with EGCG orally (50 mg/kg) in
their drinking water beginning at 8 months of age and continuing through behavioral
testing at 14 months. Because these mice had a more prevalent B6 background than Tg
APPsw mice of the intraperitoneal study, control Tg APPsw mice were not substantially
impaired in working memory at 14 months of age compared to NT controls (Figure
3.15b). Thus, the rather good performance of Tg APPsw controls precluded significant
EGCG benefit in this measure (“basement effect”), even though there was a trend for
beneficial effects of oral EGCG treatment on T5 performance during the last block of
testing (Figure 3.15b). This is further underscored by the T1 vs. T5 improvement present
during the final day of RAWM testing (Figure 3.15d), wherein all 3 groups showed
significant T1 vs. T5 improvement. However, despite the essentially
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Figure 3.15
EGCG provides cognitive benefit in Tg APPsw mice. a,c, Tg mice treated with
intraperitoneal (I.P.) injection of EGCG (20 mg/kg; n = 5) or PBS (n = 5). Similarly-aged
non-transgenic (NT) mice (n = 5) were concurrently given daily intraperitoneal injections
of PBS. For the last block of RAWM testing (a), control Tg mice were significantly
impaired versus NT controls in Trial 5 working memory errors, while Tg+EGCG mice
performed significantly better than Tg controls and no different from NT controls
(*p < 0.05). c, Only Tg+EGCG and NT controls were able to significantly decrease their
working memory errors between Trial 1 (T1) and Trial 5 (T5) on the final day of testing
(*p < 0.02 vs T1). Tg controls made substantially more T5 errors during this last day of
testing compared to the other two groups. b,d, Tg mice given oral administration of
EGCG (50 mg/kg; n = 10) in drinking water or normal H2O (n = 10). Similarly-aged NT
mice (n = 5) were concurrently given normal water daily. b, No statistical differences
were evident in T5 performance over the last block of testing. d, Animals in all three
groups were able to significantly reduce their working memory errors from T1 to T5
during the last day of testing (*p < 0.05; **p < 0.002). All group data are presented as
mean ± SEM.
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flawless performance of both NT and Tg APPsw mice treated with EGCG during T5 on
the final test day, the good performance of Tg APPsw controls resulted in both of these
groups barely missing statistical significance (p < 0.08, 0.09; Figure 3.15) when
compared to Tg APPsw controls. Nonetheless, the ability of oral EGCG treatment to
result in perfect T5 performance during the final day of testing (vs. a 2-error average for
Tg APPsw controls), strongly suggests a cognitive benefit provided by oral EGCG
treatment.

3.4 Conclusions

The studies detailed in this chapter qualify EGCG, the main naturally-occurring
polyphenolic constituent of green tea, as an effective anti-amyloidogenic and antipathogenic tau agent. Treatment with EGCG reduces Aβ generation in both APPsw
overexpressing primary neurons and neuron-like cells. In concert with these findings, αCTF generation and sAPP-α release increased in these cell lines. Accordingly, it was
clear that EGCG accomplished Aβ reductions by promoting non-amyloidogenic
proteolysis of APP. Central to this non-amyloidogenic proteolysis was α-secretase
activity, which was also directly detected to increase in APPsw N2a cells following EGCG
treatment. While initial experiments suggested that TACE/ADAM17 may be involved,
the effects of its activation were transient at best. In the following study, it became
evident that EGCG elevated α-secretase activity through enhanced activation of
ADAM10. In this study, maturation of ADAM10 correlated with both increased α-CTF
generation and sAPP-α release in both APPsw overexpressing primary neurons and
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neuron-like cells. Furthermore, EGCG was also found to promote ADAM10 maturation
in both primary microglial and N9 microglial lines, albeit with lower potency than
evidenced in neurons and neuron-like cells. To assess the level of contribution of
ADAM10 in EGCG-mediated non-amyloidogenic APP proteolysis, RNAi was performed
to knock-down expression of ADAM9, 10, or 17. Results showed that ADAM10, but not
ADAM9 or 17, was required. Investigating further upstream revealed the involvement of
PI3K signaling and furin activity in EGCG-mediated non-amyloidogenic APP
proteolysis. Interestingly, these events appear to be mutually exclusive. Therefore, it is
becoming increasingly evident that EGCG possess a multifaceted cellular/molecular
mechanism. Altogether, these data provide important mechanistic insight into the
potential use of EGCG and/or other activators of ADAM10 as therapeutic targets to
oppose cerebral amyloidosis associated with AD.
As a validation of these above findings in vivo, Tg APPsw mice were treated with
EGCG via intracerebroventricular, intrapertioneal, and oral routes. In all instances of
treatment, Aβ levels/plaque burden decreased concurrently with increases in α-CTF
generation, sAPP-α release, and α-secretase activity. While ADAM10 activation was
confirmed in orally treated animals, it was also observed in both intracerebroventricular
and intrapertioneal routes (data not shown). The effect of both intraperitoneally and
orally treated EGCG on tau pathology and cognition was also investigated. Both
intraperitoneally and orally-treated Tg APPsw mice were found to have modulated tau
profiles, with markedly suppressed sarkosyl-soluble phosphorylated tau isoforms.
RAWM testing for working memory indicated that EGCG provided cognitive benefit to
Tg APPsw mice with both routes of administration, although intraperitoneally treated
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animals showed a more pronounced benefit because of the greater impairment of their Tg
controls at the time of testing. Taken together, these data qualify α-secretase activation
as a viable anti-amyloidogenic strategy and raise the possibility that EGCG dietary
supplementation may provide effective prophylaxis for AD.
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CHAPTER 4

ANTI-AMYLOIDOGENIC PROPERTIES OF LUTEOLIN AND
STRUCTURALLY ANALOGOUS 5,7-DIHYDROXYFLAVONES

4.1 γ-Secretase inhibition
While both β and γ-secretase cleavage events are essential to the formation of an
Aβ peptide, it is the γ-secretase cleavage that determines which of the two major forms of
the peptide (Aβ1-40, 42) will be generated and consequently both the peptide’s ability to
aggregate and the rate at which it is deposited (Citron et al., 1996; Evin et al., 1995).
Thus, one clear potential therapeutic target for AD has been γ-secretase. Despite the
potential toxicity involving possible disruption of Notch signaling and intracellular
accumulation of β-CTFs, γ-secretase inhibition remains a viable anti-amyloidogenic
strategy (Barten et al., 2006; Evin et al., 2006). In addition to previous reports that novel
γ-secretase inhibitors (GSI) significantly reduced Aβ production both in vitro and in vivo
(Dovey et al., 2001; Games et al., 1995; Higaki et al., 1995; Klafki et al., 1995), Comery
and colleagues (2005) recently reported that similar GSIs may even improve cognitive
functioning in a transgenic mouse model of AD (Tg2576). These finding have
functioned to further the vigorous search for potential candidate GSIs.

4.1.1 Presenilin-1 (PS1)
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Although γ-secretase has not been entirely characterized, it is well known that it
consists of a multi-protein complex including presenilin-1 or -2 (PS1 or PS2), nicastrin,
anterior pharynx-defective-1 (APH1), and presenilin enhancer-2 (PEN2) (Sato et al.,
2007). PS1 or PS2 are believed to form the catalytic core of the γ-secretase complex.
However, deletion of the PS1 gene in mice has been reported to markedly abolish γsecretase activity, which would suggest that it is likely responsible for the majority of this
enzyme’s activity. Following endoproteolytic cleavage of PS1, the remaining dimer is
consists of a large a amino-terminal fragment (NTF) and a smaller carboxyl-terminal
fragment (CTF), which is believed to contain regulatory phospho-residues (Capell et al.,
1998). Whether endoproteolytic cleavage of PS1 is both the seminal and final required
process for γ-secretase activity remains to be determined.

4.1.2 Glycogen synthase kinase-3 (GSK-3)
Among the many promising potential candidate GSIs are the glycogen synthase
kinase 3 (GSK-3) inhibitors. These compounds target this tonically active
serine/threonine kinase, which has been implicated in several disorders of the CNS
(Carmichael et al., 2002; Engel et al., 2006; Kozlovsky et al., 2000). With regard to AD,
both isoforms of GSK-3 (α and β) have been found to directly phosphorylate tau on
residues specific to hyperphosphorylated paired helical filaments (PHF) (Ishiguro et al.,
1993), GSK-3β has been shown to phosphorylate APP and to contribute to Aβ mediated
neurotoxicity (Aplin et al., 1996; Takashima et al., 1996) and GSK-3β has been found to
phosphorylate PS1, which may act as a docking site for subsequent tau phosphorylation
(Takashima et al., 1998). Therefore, GSK-3 inhibitors are especially attractive as they
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may not only oppose Aβ generation but also NFT formation. Moreover, Phiel and
colleages (2003) reported that inhibition of the GSK-3α isoform may regulate γ-secretase
cleavage of APP in a substrate-specific manner (Phiel et al., 2003). Accordingly, this
selective inhibition of GSK-3 might provide the maximal therapeutic benefit while
reducing the potential for toxic side-effects.

4.2 Materials and methods

4.2.1 Reagents
Luteolin (> 95% purity by HPLC), was purchased from Sigma (St Louis, MO,
USA). Diosmin (> 90% purity by HPLC), was purchased from Axxora (San Diego, CA,
USA). SB-415286 was obtained from Biomol International (Plymouth Meeting, PA,
USA). Calf intestine alkaline phosphatase (CIAP) was purchased from Fermentas
(Hanover, Maryland). amino-terminal and carboxyl-terminal PS1 antibodies were
obtained from Chemicon (Temecula, California, USA), carboxyl -terminal antibody APP
369 (1:1000; kindly provided by S. Gandy and H. Steiner), carboxyl -terminal APP
antibody (1:500; Calbiochem, Temecula, CA, USA), amino-terminal APP antibody
(1:1000, 22C11; Roche, Basel, Switzerland), amino-terminal Aβ antibody 6E10 (1:1000;
Signet Laboratories, Dedham, MA, USA), phospho-GSK3α(pSer21) (1:1000; BK202;
Upstate, Lake Placid, New York, USA), antibodies against phospho-GSK3α/β
(pTyr279/216), phospho-GSK-3β (Ser9), and total GSK-3α/β (1:1000; Sigma), or actin
antibody (1:1500; as an internal reference control; Roche) were employed for western
blot analysis as described in section 2.4. Co-immunoprecitipation was performed for
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detection of APP bound to PS1 CTF by incubating 400 µg of total protein from cell
lysates with PS1 CTF antibody (1:50) as decribed in section 2.5.

4.2.2 Mice
For intraperitoneal administration of luteolin, a total of 16 (8♂/8♀) Tg APPsw
mice were used; 8 mice received luteolin, and the other 8 received vehicle (PBS).
Beginning at 8 months of age, these mice were intraperitoneally injected with luteolin (20
mg/kg) or PBS daily for 30 days based on previously described methods (chapter3).
These mice were then sacrificed at 9 months of age for analyses of Aβ levels and plaque
burdens according to methods described in sections 2.3 and 2.10. For oral administration
of diosmin, a total of 20 (10♂/10♀) APPsw mice were used; 10 mice received a diet
containing 0.05% diosmin in standard mouse chow (7012; Harlan Teklad, Madison, WI,
USA), and the other 10 received the standard diet alone. Beginning at 8 months of age,
these mice consumed both diets ad libitum for 6 months. These mice were then
sacrificed at 14 months of age for analyses of Aβ levels and plaque burdens according to
methods described in sections 2.3 and 2.10. GSK-3α/β immunohistochemical staining
was performed using anti-phospho-GSK-3/α/β (pTyr279/216) antibody (1:50) in
conjunction with the VectaStain Elite™ ABC kit (Vector Laboratories, Burlingame, CA,
USA) coupled with diaminobenzidine substrate according to methods described in
section 2.10.

4.3 Results
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4.3.1 Luteolin inhibits Aβ1-40, 42 generation from SweAPP N2a cells and Tg APPsw
mouse-derived primary neuronal cells
To examine the effects of luteolin on APP metabolism, APPsw N2a cells and
primary neuronal cells derived from Tg APPsw mice were treated with a wide range of
concentrations of the flavonoid for 12 hours. Following a series of analyses, of which
involved immunoprecipitation, western blot, and ELISA, data revealed that luteolin
effectively reduced both Aβ1-40, 42 production in either cell line in a concentration
dependent manner (Figure 4.1a,c). In fact, luteolin markedly abolished generation of
both Aβ peptides with >70% and >85% reductions at treatment concentrations of 20 and
40 µM, respectively (Figure 4.1a,c). Furthermore, to determine at which level luteolin
impacts APP metabolism, CTF profiles of SweAPP N2a cells and primary neuronal cells
derived from Tg APPsw mice were investigated following treatment. As illustrated in
Figure 4.1b and d, western blot analysis shows a concentration dependent accumulation
of both α and β−CTFs, approximately 2-3 fold increases in either cell line. Given the
obvious implications on γ-secretase activity, SweAPP N2a cells and primary neuronal
cells derived from Tg APPsw mice were treated with an range of concentrations of
luteolin for various periods of time and lysates were subjected to fluorometric assay for γcleavage. In accordance with expectations, luteolin lowered γ-secretase cleavage activity
in both a concentration and time dependent fashion (Fig. 4.1e,f). More importantly, these
concentration and time dependent decreases in γ-secretase cleavage activity correlate
with the decreases in total Aβ generation in cultured media, as determined by ELISA
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Figure 4.1a-d
Luteolin inhibits Aβ1-40, 42 generation from SweAPP N2a cells and Tg APPsw mousederived primary neuronal cells. SweAPP N2a cells (a, b) or Tg APPsw mouse-derived
primary neuronal cells (c, d) were treated with luteolin at various concentrations as
indicated for 12 hours.
a, c, Secreted Aβ1-40, 42 peptides were analyzed by
immunoprecipitation/Western blot (right) and ELISA (left; n = 3 for each condition) in
cell cultured media. For Aβ ELISA, data are represented as a percentage of Aβ1-40, 42
peptides secreted 12 hours after luteolin treatment relative to control (untreated). b, d,
APP CTFs were analyzed by western blot (right) in cell lysates and relative fold mean
over control (α, β-CTF) was calculated by densitometric analysis (left). a, b, c, d, Oneway ANOVA followed by post hoc comparison revealed significant differences between
each concentration (p < 0.005) except between 20 µM and 40 µM (p> 0.05).
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Figure 4.1e and f
Luteolin inhibits Aβ1-40, 42 generation by reducing γ-secretase activity in SweAPP N2a
cells. SweAPP N2a cells were treated with luteolin at a single concentration (20 µM) for
various time points as indicted. e, f, Secreted Aβ1-40, 42 peptides were analyzed in
conditional media by ELISA following 12 hours incubation (top panel; n = 3 for each
condition) and γ-secretase activity was analyzed in cell lysates following 90 min
incubation using secretase cleavage activity assay (lower panel; n = 3 for each condition).
e,f, Data presented as a percentage of fluorescence units/milligrams protein activated 30,
60, 90, 120, 300 minutes after luteolin treatment relative to control (untreated). e,f, Oneway ANOVA followed by post hoc comparison revealed a significant difference between
each time point examined (p < 0.005).
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(Figure 4.1e,f). Taken together, the above data suggests that luteolin exerts its antiamyloidogenic effects through down-regulation of γ-secretase activity.

4.3.2 Luteolin reduces GSK-3α/β activation in SweAPP N2a cells and Tg APPsw
mouse-derived primary neuronal cells
To establish a mechanism whereby luteolin modulates γ-secretase activity and
subsequent Aβ generation, the effect this flavonoid had on a variety of proteins related to
and/or required for proper functioning of the γ-secretase complex were investigated.
Interestingly, treatment with an effective concentration of luteolin (20 µM) increased
levels of serine 21 phosphorylated inactive GSK-3α isoforms in lysates from both
SweAPP N2a cells and Tg APPsw mouse-derived primary neuronal cells (Figure 4.2).
However, no significant changes in overall expression of either GSK3-α or β were
observed by western blot, confirming that this phenomenon most likely occurs at the
post-translational or protein stage of this kinase (Figure 4.2). In addition, this increase in
GSK-3α serine 21 residue phosphorylation-mediated inactivation continued through 3
hours (Figure 4.2b,e). At the same time, it is evident that levels of tyrosine 279
phosphorylated active GSK-3α isoforms decreased in a time dependent manner (Figure
4.2b,e). More to the point, these time dependent decreases in phospho-tyrosine 279
active GSK-3α are quite congruent with the increases observed with phospho-serine 21
inactive isoforms (Figure 4.2). Figure 4.2c and f clearly indicate abrupt decreases in
active phosphorylated isoforms and increases in inactive phosphorylated isoforms within
60 minutes of luteolin treatment. Also notable, following 2 hours of treatment, levels of
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Figure 4.2a-c
Luteolin reduces GSK-3α/β activation in SweAPP N2a. SweAPP N2a cells were treated
with luteolin at 20 µM for various time points as indicated. Cell lysates were prepared
and subjected to western blot analysis for phosphorylated forms of GSK-3α/β. a,
Western blot analysis using anti-phospho-GSK-3α (Ser21) antibody shows one band (51
kDa) corresponding to phosphorylated form of GSK-3α or using anti-GSK-3 monoclonal
antibody recognizes both total GSK-3α and GSK-3β, 51 and 47 kDa, respectively.
Western blot analysis using anti-Actin antibody shows Actin protein (as an internal
reference control). Densitometric analysis reveals the ratio of phospho-GSK-3α (Ser21)
to total GSK-3α as indicated below the figures (n = 3 for each condition). a, One-way
ANOVA followed by post hoc comparison revealed a significant difference between 0
min and 5, 10, 15, 20 or 25 minutes (p< 0.001). b, Western blot analysis using antiphospho-GSK-3α/β(Tye279/216) antibody shows two bands (51 and 47 kDa) corresponding
to phosphorylated forms of GSK-3α and GSK-3β or using anti-phospho-GSK-3β (Ser9)
antibody recognizes phosphorylated form of GSK-3β at 47 kDa. Anti-Actin antibody
was used as shows an internal reference control. Densitometric analysis reveals the ratio
of phospho-GSK-3α (Tye279/216) to total GSK-3α as indicated below the figures (n = 3 for
each condition). b, One-way ANOVA followed by post hoc comparison significant
difference was noted between 30 min and 45, 60, 75, 90, 120, 150 or 180 min (p <
0.005). For c, plots comparing ratios of phospho-GSK-3α (Ser21) and phospho-GSK3α/β(Tye279/216) to total GSK-3α from densitometric analysis of western blots over time.
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Figure 4.2d-f
Luteolin reduces GSK-3α/β activation in Tg APPsw mouse-derived primary neuronal
cells. Tg APPsw mouse-derived primary neuronal cells were treated with luteolin at 20
µM for various time points as indicated. Cell lysates were prepared and subjected to
western blot analysis for phosphorylated forms of GSK-3α/β. d, Western blot analysis
using anti-phospho-GSK-3α (Ser21) antibody shows one band (51 kDa) corresponding to
phosphorylated form of GSK-3α or using anti-GSK-3 monoclonal antibody recognizes
both total GSK-3α and GSK-3β, 51 and 47 kDa, respectively. Western blot analysis
using anti-Actin antibody shows Actin protein (as an internal reference control).
Densitometric analysis reveals the ratio of phospho-GSK-3α (Ser21) to total GSK-3α as
indicated below the figures (n = 3 for each condition). d, One-way ANOVA followed by
post hoc comparison revealed a significant difference between 0 min and 5, 10, 15, 20 or
25 minutes (p< 0.001).
e, Western blot analysis using anti-phospho-GSK279/216
3α/β(Tye
) antibody shows two bands (51 and 47 kDa) corresponding to
phosphorylated forms of GSK-3α and GSK-3β or using anti-phospho-GSK-3β (Ser9)
antibody recognizes phosphorylated form of GSK-3β at 47 kDa. Anti-Actin antibody
was used as shows an internal reference control. Densitometric analysis reveals the ratio
of phospho-GSK-3α (Tye279/216) to total GSK-3α as indicated below the figures (n = 3 for
each condition). e, One-way ANOVA followed by post hoc comparison significant
difference was noted between 30 min and 45, 60, 75, 90, 120, 150 or 180 min (p <
0.005). For f, plots comparing ratios of phospho-GSK-3α (Ser21) and phospho-GSK3α/β(Tye279/216) to total GSK-3α from densitometric analysis of western blots over time.
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phospho-tyrosine 216 active GSK-3β drop off, which may also explain, in part, the
luteolin-mediated effects on the γ-secretase complex via PS1. Although luteolin clearly
affects that of GSK-3α, no such significant changes in phospho-serine 9 GSK-3β
inactivation were detected. Therefore, when considering the above data, it is apparent
that luteolin affects GSK-3α/β signaling and confirms that this signaling is a potential
upstream event required for modulation of γ-secretase activity.

4.3.3 GSK-3 inhibition alters PS1 processing/phosphorylation in SweAPP N2a cells
As indicated by panels a,b,c of Figure 4.3, western blot analysis of carboxylterminal portions of PS1 reveals three distinct bands. The two bands of highest
molecular weight, approximately 20 kDa and 18 kDa in size, most likely represent
previously reported phosphorylated PS1 CTFs with the smaller 16 kDa band representing
the more common CTF product indicative of PS1 endoproteolytic cleavage. Following
treatment of SweAPP N2a cells with various concentrations of luteolin, lysates revealed
that PS1 CTF phosphorylation increased. Significant differences in phospho-PS1
CTF:PS1 CTF ratios with luteolin treatment were evident, both concentration and time
dependently (Figure 4.3a). More to the point, these trends correlated with the
concentration and time dependent decreases in Aβ1-40, 42 generation. To confirm that the
20 kDa and 18 kDa bands were representative of phosphorylated PS1 isoforms, APPsw
N2a cells were again treated with luteolin (20 µM) prior to lysis and subsequently cell
lysates were incubated with calf intestine alkaline phosphatase (CIAP) to
dephosphorylate any potential phosphorylated proteins, which consequently may have
skewed electrophorectic mobilities. Indeed, following 30 minutes of incubation, the 20
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Figure 4.3
PS1 phosphorylation is associated with luteolin-mediated inhibition of Aβ generation.
SweAPP N2a cells were treated with luteolin at a range of concentrations for 4 hours or
at 20 µM for various time points as indicated. Cell lysates were prepared from these cells
and subjected to western blot analyses of PS1 carboxyl-terminal fragments (CTFs) (a)
and amino-terminal fragment (NTFs) (c). Western blot analysis by anti-PS1 CTF
antibody shows two bands corresponding to phosphorylated PS1 CTF (p-CTF) and one
dephosphorylated PS1 CTF (CTF). While western blot analysis by anti-PS1 CTF
antibody shows tow bands corresponding to holo-PS1 and PS1 NTF. b, cell lysates from
luteolin treated cells (20 µM) were incubated with calf-intestine alkaline phosphatase
(CIAP) or buffer for various time points. Western blot analysis by anti-PS1 CTF
antibody confirms two higher molecular weight bands corresponding to phosphorylated
isoforms. Densitometric analysis reveals the ratio of PS1 p-CTF to CTF below figures.
A t test revealed a significant deference between luteolin concentrations and time points
for ratio of PS1 p-CTF to CTF (p < 0.005 with n = 3 for each condition, but not for ratio
of holo-PS1 to PS1 NTF (p> 0.05 with n = 3 for each condition) at each time point
examined. Cultured media were collected for Aβ ELISA. Data corresponds to
percentage of Aβ1-40, 42 peptides secreted 4 hours after luteolin treatment relative to
control (untreated) as indicated below panel a.
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kDa band is not evident in the CIAP treated lysates (Figure 4.3b). Also the 18 kDa band
is clearly reduced and the endogenous CTF, 16 kDa, appears to accumulate. When
compared to lysates incubated with only reaction buffer, time dependent decreases in
phosphorylated residues are apparent by ratios of the 20 kDa CTF:16 kDa CTF (Figure
4.3b) While luteolin treatment influenced PS1 CTF species, this compound had no
significant effect on either full-length PS1 or PS1 NTF protein levels (Figure 4.3c).
Luteolin therefore appears to affect PS1 phosphorylation and may indicate a means by
which γ-secretase activity may be regulated.
To determine if this phenomenon was specifically attributable to luteolin treatment or
more generally in regards to GSK-3 inhibition, SweAPP N2a cells were treated with an
effective concentration of GSK-3 inhibitor SB-415286 (20 µM) for various periods of
time (Figure 4.4a). Again, similar decreases in Aβ1-40, 42 generation (data not shown) and
alterations in phospho-PS1 CTF:PS1 CTF ratios were evident following SB-415286
treatment (Figure 4.4a). Furthermore, to substantiate the role of GSK-3α in this luteolinmediated PS1 processing, RNAi knock-down was conducted and successfully knockeddown the expression of both GSK-3α and β (>70%, data not shown) in SweAPP N2a
cells. As expected, GSK-3α siRNA transfected cells exhibited significantly higher
phosphorylated PS1 isoforms as compared to GSK-3β siRNA or mock transfectants
(Figure 4.4b). Similar differences were observed when comparing the level of PS1
phosphorylation in luteolin treated (20 µM) cells to that of GSK-3 β siRNA or mock
transfectants (Figure 4.4b). This data suggests that GSK-3α may regulate PS1 CTF
phosphorylation and
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Figure 4.4
GSK-3α regulates PS1 phosphorylation. a, SweAPP N2a cells were treated with a known
GSK-3 inhibitor (SB-415286) at 20 µM for various time points. Western blot analysis by
anti-PS1 CTF antibody produces a similar phosphorylation profile to that of luteolin
treated cells. Densitometric analysis reveals the ratio of PS1 p-CTF to CTF and ratio of
holo-PS1 to Actin as indicated below the figures. A t test revealed significant differences
between time points for the ratio of PS1 p-CTF to CTF (p< 0.001 with n = 3 for each
condition). b, expression of PS1 CTFs was analyzed by western blot in cell lysates from
SweAPP N2a cells transfected with siRNA targeting GSK-3α, β, or mock transfected 48
hours post-transfecion. Prior to experiments, siRNA knockdown efficiency >70% for
GSK-3α, β was confirmed by Western blot analysis (data not shown). Densitometric
analysis reveals the ratio of PS1 p-CTF to CTF as indicated below the each panel. A t
test revealed significant differences between GSK-3α siRNA-transfected cells and GSK3β siRNA or control (Mock transfected cells) (p < 0.001 with n = 4 for each condition)
on the ratio of PS1 p-CTF to CTF. In addition, a t test also revealed significant
differences between luteolin treated cells and GSK-3β siRNA or control (Mock
transfeced cells) (p < 0.001 with n = 4 for each condition) on the ratio of PS1 p-CTF to
CTF.
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additionally that this 20 kDa phospho-PS1 CTF band may represent a less active or nonamyloidogenic form of γ-secretase.

4.3.4 GSK-3α regulates PS1-APP association in SweAPP N2a cells
Although previous study has linked GSK-3 inhibitors to reduced Aβ generation
through the γ-secretase complex (Phiel et al., 2003), the manner in which this complex’s
activity is affected remains unclear. To clarify how phospho-PS1 CTF isoforms may
regulate γ-secretase activity, cell lysates of luteolin, SB-415286, and GSK-3α siRNA
treated SweAPP N2a cells were immunoprecipitated by PS1 antibody and probed for
APP (Figure 4.5). As illustrated in panel a of Figure 4.5, the APP-PS1 association is
significantly disrupted by not only luteolin and SB-415286 treatment, but also by GSK3α siRNA. Moreover, this treatment mediated disruption has no correlation to full-length
APP levels (Figure 4.5b). This analysis suggests that treatment has little effect on APP
expression/trafficking. Thus, it is likely that GSK-3α or, more specifically, downstream
phosphorylation of the PS1 CTF plays an essential role in regulating the association of γsecretase complex with its APP substrate.

4.3.5 Luteolin treatment reduces GSK-3 activation and results in reduction of Aβ
pathology in Tg APPsw mice
To validate the above findings in vivo, 8 month-old Tg APPsw mice were treated
with 20 mg/kg luteolin administered by daily intraperitoneal injection for 30 days. Brain
homogenates from these mice were subsequently analyzed by immunoprecipitation,
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Figure 4.5
GSK-3α regulates PS1-APP association. SweAPP N2a cells were treated with either
luteolin (20 µm) SB-415286 (20 µm) for 4 hours. Cell lysates from these treated cells
and GSK-3α siRNA-transfected cells were subsequently analyzed by
immunoprecipitation/western blot. a, lysates were immunoprecipitated by anti-PS1 CTF
antibody. Densitometric analysis of western blot by 6E10 antibody reveals the ratio of
APP to IgG as indicated below panel a. A t test revealed significant differences between
all treatments and control (p < 0.001 with n = 3 for each condition). b, cell lysates were
analyzed by western blot by 6E10 antibody. Densitometric analysis of western blot by
anti-Actin antibody reveals no significant changes in the ratio of APP to Actin as
indicated below panel b (p > 0.05).
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western blot, and ELISA (Figure 4.6). As shown in panel a of Figure 4.6, both GSK3α/β active isoforms from the homogenates of luteolin treated mice are reduced when
compared to control. Moreover, ratios of each phosphorylated GSK-3 isoform to its
respective total protein revealed a significant decrease in activation with treatment
(Figure 4.6a). These decreases in activation are also apparent in the
immunohistochemical analysis of GSK-3α/β activity in neurons of the CA1 region of the
hippocampus and regions of the cingulate cortex (Figure 4.6c). Western blot analysis of
PS1 from treated mice interestingly shows significantly lower levels of PS1 processing
by CTF to Actin ratios (Figure 4.6b). To further confirm luteolin’s mechanism in this
model, brain homogenates were immunoprecipitated by PS1 antibody and probed for
APP. As expected, luteolin treatment effectively abolished the PS1-APP association
(Figure 4.6d). In addition, no significant changes in holo-APP expression following
treatment were observed. Interestingly, a potential decrease in oligomeric forms of Aβ
was detected as illustrated in panel e of Figure 4.6. Finally, to assess this potential
decrease, ELISA of both soluble and insoluble Aβ1-40, 42 was conducted (Figure 4.6f).
Luteolin treatment markedly reduced both soluble isoforms of Aβ by 25% and 49%,
respectively (Figure 4.6f). Although no such significant reductions in insoluble Aβ
isoforms were evident (Figure 4.6f), one would expect this result given the age and
consequent low plaque burden of these Tg APPsw mice. All together, the above lines of
evidence suggest luteolin treatment can attenuate ongoing AD pathology in vivo and does
so through GSK-3-mediated regulation of PS1/γ-secretase activity.

4.3.6 Oral administration of diosmin reduces Aβ pathology in Tg APPsw mice
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Figure 4.6a and b
Luteolin treatment reduces GSK-3 activation and PS1 CTF expression in Tg APPsw mice.
Brain homogenates from Tg APPsw mice treated with luteolin (n = 5) or vehicle (PBS, n
= 5). a, homogenates were analyzed by western blot with active and holo anti-GSK-3
antibodies with anti-Actin antibodies as an internal control. Densitometric analysis
reveals the ratio of active phosphorylated GSK-3α/β to holo-GSK-3. A t test reveals
significant reductions in both active GSK-3α and β isoforms from luteolin treated
animals compared to control (p <0.001). b, homogenates were analyzed by western blot
with anti-PS1 CTF or NTF antibody. Densitometric analysis reveals the ratio of PS1
CTF or NTF to Actin (internal control). A t test shows significant reductions in PS1 CTF
levels with luteolin treatment (p <0.001), but not for PS1 NTF levels (p > 0.05).
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Figure 4.6c
Luteolin treatment reduces GSK-3 activation in Tg APPsw mice. Brain sections from Tg
APPsw mice treated with luteolin (n = 5) or vehicle (PBS, n = 5). c, immunochemistry
staining analysis for active phosphorylated GSK-3α/β.
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Figure 4.6d-f
Luteolin treatment inhibits PS1-APP association and results in reduction of Aβ pathology
in Tg APPsw mice. Brain homogenates from Tg APPsw mice treated with luteolin (n = 5)
or vehicle (PBS, n = 5). d, homogenates were immunoprecipitated by anti-PS1 CTF
antibody. Densitometric analysis of western blot by 6E10 antibody reveals the ratio of
APP to IgG. A t test revealed significant differences between luteolin treatment and
control (p <0.001). e, homogenates were analyzed by western blot by 6E10 antibody.
Approximately 12 kDa band may represent oligomeric form of amyloid. Densitometric
analysis of western blot by anti-Actin antibody reveals no significant changes in the ratio
of APP to Actin. f, soluble and insoluble Aβ1-40, 42 peptides from homogenates were
analyzed by ELISA. For Aβ ELISA, data are represented as picograms of peptide
present in milligrams of total protein. Luteolin treatment results in markedly reduced
soluble Aβ1-40, 42 levels, 25% and 49%, respectively (top panel). No significant
reductions in insoluble Aβ isoforms following treatment were observed (bottom panel).
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Previous pharmacokinetic studies suggest luteolin has an oral bioavailability < 2% and a
half-life in plasma < 4 hrs, which would make it a poor candidate compound for oral
clinical trials (Shimoi et al., 1998; Wittemer et al., 2005). Taking this situation into
consideration, other compounds with a 5,7-dihydroxyflavone structural backbone were
screened to identify a more suitable flavonoid for oral administration (Figure 4.7). One
compound, diosmetin, proved to be just as efficacious as luteolin in promoting PS1 CTF
phosphorylation and consequently inhibiting γ-secretase activity in SweAPP N2a cells
(data not shown). Cova and colleagues (1992) reported that the flavonoid diosmin, a
well-evidenced vascular protecting agent, is rapidly transformed by intestinal flora to its
aglycone form, diosmetin. Taken in this manner, diosmetin was found to be readily
absorbed and rapidly distributed throughout the body with a plasma half-life > 26 hrs
(Cova et al., 1992). To determine whether oral administration of diosmin, as a parent
compound for diosmetin, could have similar anti-amyloidogenic effects in vivo as
luteolin, Tg APPsw mice were orally treated with 0.05% diosmin supplemented or control
diet at 8 months of age for 6 months. As shown in Figure 4.8, diosmin treatment
similarly reduced cerebral amyloidosis in these mice. Image analysis of micrographs
from Aβ antibody (4G8) stained sections reveals that plaque burdens were significantly
reduced throughout the brain (Figure 4.8a,b). To verify the findings from these coronal
sections, brain homogenates for Aβ levels were analyzed by ELISA. Again, diosmin oral
treatment markedly decreased both soluble and insoluble forms of Aβ1-40, 42 (Figure 4.8c).
Taken together, the above data confirm an oral route of administration of diosmin
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Figure 4.7
Chemical structures of the 5,7-dihydroxyflavone compounds.
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Figure 4.8
Oral administration of diosmin reduces Aβ pathology in Tg APPsw mice. Brain
homogenates and sections from Tg APPsw mice treated with 0.05% diosmin
supplemented diet (n = 10) or control diet (n = 10). a, half-brain coronal sections were
analyzed by Aβ antibody, 4G8 staining. b, percentage of 4G8 positive plaques (mean ±
SEM) was quantified by image analysis. A t test for independent samples revealed
significant differences (p < 0.001) between groups. c, total soluble and insoluble Aβ1-40,
For Aβ ELISA, data are
42 peptides from homogenates were analyzed by ELISA.
represented as picograms of peptide present in milligrams of total protein. Diosmin
treatment results in markedly reduced total soluble and insoluble Aβ1-40, 42 levels, 37%
and 46%, respectively. A t test for independent samples revealed significant differences
(p < 0.005) between groups.
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provides effective, if not superior, attenuation of amyloid pathology comparable to that of
intraperitoneal injected luteolin.

4.4 Conclusions
The studies detailed in this chapter qualify the flavonoid luteolin, and structurally similar
compounds diosmetin and disomin, as effective anti-amyloidogenic agents. Treatment
with luteolin reduces Aβ generation in both APPsw overexpressing primary neurons and
neuron-like cells. Interestingly, luteolin induces changes consistent with GSK-3
inhibition that decrease amyloidogenic γ-secretase APP proteolysis and promote PS1
CTF phosphorylation. Following investigation of the contribution of GSK-3 in this
mechanism, data revealed that GSK-3α activity was essential for both PS1 CTF
phosphorylation and PS1-APP interaction. As validation of these findings in vivo,
luteolin, when applied to the APPsw mouse model of AD, decreased soluble Aβ levels,
reduced GSK-3 activity, and disrupted PS1-APP association. In addition, Tg APPsw mice
treated with diosmin, a glycoside of diosmetin, display significantly reduced
Aβ pathology. Taken together, these data suggest GSK-3 inhibition is a viable
therapeutic approach for AD by impacting PS1 phosphorylation-dependent regulation of
amyloidogenesis.

101

CHAPTER 5

DISCUSSION

5.1 EGCG-mediated non-amyloidogenic APP proteolysis
Previous reports have shown that green tea components such as EGCG have
neuroprotective properties; however, a clear cellular/ molecular mechanism underlying
these effects has hitherto not been established (Mandel et al., 2004). The studies detailed
in Chapter 3 show that EGCG promotes non-amyloidogenic APP proteolysis in vitro and
in vivo, and that it accomplishes this by promoting α-secretase activity. A previous study
by Jeong and colleagues (2003) suggested that EGCG might act as a β-secretase inhibitor
in a cell-free system, raising the possibility that EGCG-mediated inhibition of Aβ
generation may be accomplished via direct blockade of BACE activity. To address this
possibility, SweAPP N2a cells were treated with the BACE inhibitor (data not shown).
Importantly, treatment with an effective concentration of the inhibitor failed to mimic the
increased α-CTF and sAPP-α levels observed following EGCG treatment. Rather, it
appears that there may actually be a slight increase in β-secretase activity, as depicted in
Figure 3.2a and c. This increase may be an indication of the extent of competition for
APP between the two pathways or an effect of the underlying anti-amyloidogenic
mechanism of EGCG.
While both TACE/ADAM17 and ADAM10 were implicated as the potential αsecretase affected by EGCG, the induction of TACE/ADAM17 appears to be transient.
In addition, TACE/ADAM17 protein levels were not significantly altered in brain
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homogenates derived from EGCG treated Tg APPsw mice (data not shown). However,
TAPI-1, a TACE/ADAM17 inhibitor, significantly attenuated the effect of EGCG on
promoting α-secretase cleavage of APP. This inhibition may be explained by the
possibility of off-target effects of TAPI-1, namely by inhibiting ADAM10. The transient
role of TACE/ADAM17 may also be an effect of the underlying anti-amyloidogenic
mechanism of EGCG. It is well known that TACE/ADAM17 is a multifunctional
molecule that has been shown to be critically involved in TNF-α maturation associated
with pro-inflammatory responses (Moro et al., 2003). Because TACE/ADAM17 has not
been shown to exhibit substrate preference for TNF-α versus APP, EGCG may also
transiently, via increasing TACE/ADAM17 levels, promote TNF-α maturation and
release in cultured primary murine microglial cells. Interestingly, no elevation of TNF-α
levels were detectable in cultured media from primary microglial cells (data not shown).
This observation is consistent with other reports, in which EGCG treatment actually
inhibits TNF-α expression and subsequently neuronal damage (Suganuma et al., 2000; Li
et al., 2004). Because microglia must first undergo coordinated activation in response to
innate immune stimuli to cleave pro-TNF-α and subsequently secrete TNF-α, a likely
explanation for why EGCG does not elicit TNF-α release from murine microglia is that it
does not trigger microglial activation and may in fact be immunosuppressive.
Upon further examination it was clear that EGCG treatment primarily induced
increases in ADAM10 maturation. Moreover, these elevations even persisted after 18
hours (data not shown), thereby differentiating the effect of EGCG on ADAM10 from the
more transient (less than 5 h) effect on TACE/ADAM17. This robust increase in mature
ADAM10 agrees with studies conducted by Stoeck and colleagues (2006), suggesting
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that TACE/ADAM17 displays transient “inducible” activity mediated by protein kinase C
activation, whereas ADAM10 achieves inducible and “constitutive” activity for substrate
processing. Indeed, EGCG induced dramatic increases in ADAM10 maturation after only
30 minutes and through to 2 hours, at which time there was a drop off in pro-ADAM10
isoforms. These data in combination with semi-quantitative RT-PCR analysis of
ADAM10 RNA expression suggested that EGCG activated ADAM10 predominantly at
the post-translational level, possibly through the proteolysis of this zymogen pro-form.
Curiously, whereas the ~75 kDa form of ADAM10 is reduced in N9 microglia cells
(Figure 3.5a) and nearly absent from primary cells (Figure 3.5b), it does not significantly
change after EGCG treatment and could represent a previously reported ADAM10 nonglycosylated isoform (Chubinskaya et al., 2001; Reiss et al., 2005).
Initial data, and reports by others (Asai et al., 2003; Selkoe, 2001) suggesting that
one or multiple ADAM family members play(s) dominant roles in inducible and/or
constitutive methods of substrate processing, also led to the examination of which of the
putative α-secretases analyzed here were required and whether inter-α-secretase
modulation (Cisse et al., 2005) was involved in EGCG-mediated non-amyloidogenic APP
proteolysis. As expected, siRNA knockdown of ADAM10 primarily blocked EGCG
induction of APP α-secretase metabolism (Figure 3.8a,b). In addition, siRNA knockdown of TACE/ADAM17 also slightly inhibited EGCG modulation of APP metabolism
(Figure 3.5a), again in accordance with the previous findings of the transient role of
TACE/ADAM17. These observations, coupled with the findings that anti-ADAM10
siRNA failed to affect ADAM9 or -17 protein levels (Figure 3.7d), greatly diminishes the
probability of the involvement of intermolecular regulation between ADAMs as a
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contributing factor in EGCG-mediated APP metabolism. Thus, whereas ADAM9 and/or 17 may play minor or transient roles in EGCG modulation of APP metabolism, ADAM10 appears to be the major downstream effector.
Mechanisms governing ADAM10 activation are currently not fully understood,
yet studies have implicated PC family members, particularly furin and PC7 (Anders et al.,
2001), as mediators of proteolytic activation of ADAM10. Additionally, maturation of
various matrix metalloproteases (MMPs) has been reported to be PI3K-dependent
(Zahradka et al., 2004). Accordingly, EGCG-mediated ADAM10 maturation appears to
involve both furin and PI3K. These findings suggest that furin activates ADAM10 in the
TGN, as PI3K inhibition may prevent appropriate vesicular trafficking. Interestingly,
furin is also involved in proteolysis of the N-glycosylated zymogen/pro-form of BACE
and TACE/ADAM17, which may explain the transient increases in the activity both of
these enzymes following EGCG treatment (Anders et al., 2001; Annaert and De Strooper,
2002). Additionally, overexpression of full-length BACE reduces sAPP-α while driving
β-CTF production, and only moderately increases Aβ formation; whereas overexpression
of mature BACE results in dramatic increases in Aβ production (Benjannet et al., 2001;
Bennett et al., 2000). Altogether, these data suggest an attractive notion whereby furin
may be rate-limiting for the proteolytic activation of both BACE and α-secretases.
Accordingly, imbalances in substrate processing by furin could represent a mechanism of
disease.
Direct and/or indirect molecular interactions between EGCG and ADAM10
remain to be determined. As EGCG is an ampiphatic small molecule, it is very likely that
it reaches its molecular target by passive diffusion through cell membranes. This means
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of cellular uptake may explain the rapid onset of ADAM10 maturation observed
following EGCG treatment (Figure 3.4c) and suggests an intracellular molecular target,
such as PI3K. On the other hand, cell surface receptor interactions have also been
suggested (Fujimura et al., 2005; Rodriguez et al., 2006) and may also involve PI3K
signaling. However, as both furin activity and PI3K signaling appear to be mutually
exclusive it is likely that EGCG may affect multiple cellular targets, likely owing this
phenomenon to its pleiotropic nature. Future studies will be needed to further establish
the molecular mechanism(s) whereby furin and PI3K regulate EGCG-mediated ADAM10
maturation and enhancement of non-amyloidogenic APP proteolysis.

5.2 5,7-Dihydroxyflavone-mediated PS1 CTF phosphorylation
Although previous reports have substantiated the therapeutic potential of GSK-3
inhibitors in AD (Engel et al., 2006; Hong et al., 1997; Munoz-Montano et al., 1997;
Phiel et al., 2003) the underlying anti-amyloidogenic mechanisms have hitherto not been
established. Through the studies detailed in Chapter 4 a mechanism is elucidated
whereby these GSK-3 inhibitors may reduce amyloidosis. It is apparent that reductions
in GSK-3α activation, whether achieved by pharmacological means or by genetic
silencing, promoted the phosphorylation of the CTF of PS1, which subsequently
disrupted the enzyme-substrate association with APP. As in vitro validation, significant
increases in PS1 CTF phosphorylation (20 kDa isoforms) were observed following
luteolin, SB-415286, and GSK-3α RNAi treatment, which act with similar potentcy
(luteolin and SB-415286) and efficacy (Fig. 4.4). Moreover, both in vitro and in vivo
analysis revealed significant reductions in APP co-immunoprecipitated with PS1
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following treatment (Figure 4.5a,b and Figure 4.6d,e). Accordingly, it is fair to expect
the concentration and time dependent reductions in Aβ1-40, 42 generation following
treatment that were observed in Figure 4.1e and f. Even though it is apparent that γsecretase activity also concentration and time dependently decreased (Figure 4.1e,f), it is
unclear how this protein complex is affected. GSK-3α inhibition may potentially affect
complex formation; however, no changes in the expression of PS1, nicastrin, PEN2, or
APH-1 were observed following treatment (data not shown). Furthermore, GSK-3α
inhibition did not appear to phosphorylate full-length PS1 and did not affect
endoproteolytic cleavage based on PS1 NTF analysis (Figure 4.3c). Although no
phospho-PS1 CTFs species were detected in vivo, there were clear reductions in the 16
kDa PS1 CTF bands (Figure 4.6b), which are presumably indicative of a more highly
active, amyloidogenic γ-secretase complex. Therefore, it is likely that these compounds
affect γ-secretase at the level of the CTF of PS1. However, it remains to be seen if
phosphorylation of the CTF of PS1 is a required step for γ-secretase inhibition/Aβ
reduction mediated by luteolin. There are some obvious complexities to the mechanism
of dimerization of PS1 along with subsequent association with other essential γ-secretase
components such as nicastrin, which recent studies suggest may function as the γsecretase substrate receptor (Shah et al., 2005). Accordingly, it will now be important to
determine at what residue(s) this 20 kDa phospho-PS1 CTF is phosphorylated and
subsequently how it interacts with PS1 NTFs or nicastrin.
Some of the earliest work investigating the activity of PS1 endoproteolytic
fragments and the oligomerization of the γ-secretase complex has already identified two
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human phosphorylated PS1 CTFs (Seeger et al., 1997; Walter et al., 1997). What is
more, the presence of these aforementioned phosphorylated PS1 CTFs corresponded with
both reduction of Aβ generation and accumulation of the β-CTF of APP (Buxbaum et al.,
1990; Seeger et al., 1997; Walter et al., 1997), which is evidenced following luteolin
treatment (Fig. 1). It is also important to note that the accumulation β-CTFs following
luteolin treatment is a mere fraction of that seen when compared to the use of a direct γsecretase inhibitor (data not shown). In view of this finding, it becomes increasingly
evident that selective GSK-3 inactivation may be a less toxic, more regulative, substratespecific mode of γ-secretase inhibition. Given the fact that the above earlier studies
routinely employed the use of phorbol-12,13-dibutyrate (PDBu), a potent PKC activator,
as their phosphorylating agent (Buxbaum et al., 1990; Seeger et al., 1997; Walter et al.,
1997) it was possible that luteolin was similarly acting as a PKC activator, rather than a
GSK-3 inhibitor. Co-treatment of SweAPP N2a cells with luteolin or SB-415286 and the
PKC inhibitor GF109203X had no effect on GSK-3 inhibition (data not shown).
However, minor decreases in both 20 kDa and 18 kDa phospho-PS1 CTF isoforms
following GF109203X treatment were observed, indicating that PKC may play a part
either in the downstream signaling mechanism or by directly phosphorylating the PS1
CTF (data not shown). Additionally, there were no indications that GSK-3α inhibition
affected non-amyloidogenic proteolysis of APP as luteolin, SB-415286, and GSK-3α
RNAi treatment had no effect on the maturation of TACE/ADAM17, ADAM10, or
sAPP-α release (data not shown), which are all strongly associated with PKC activation
(Buxbaum et al., 1998; Checler, 1995; Hung et al., 1993; Lopez-Perez et al., 2001).
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Collectively, these data suggest that GSK-3α may be an upstream regulator of PS1 CTF
phosphorylation and consequently of γ-secretase activity.
However, it must be noted that although changes consistent with GSK-3
inhibition following luteolin treatment were observed, it remains unclear whether or not
this flavonoid is a direct inhibitor of this kinase. What seems to be evident, and a point at
which it potentially differs from direct GSK-3 inhibitors (including SB-415286), is that
luteolin treatment appears to preferentially inactivate GSK-3α isoforms over β isoforms
(Figure 4.2). That is to say, luteolin treatment did appear to reduce active GSK-3β
isoforms expressed at about 2 hours (Figure 4.2b,e), as compared to control (data not
shown), but expression of active GSK-3α isoforms was more timely and effectively
reduced (Figure 4.2b,e). Remarkably, β-catenin remained unaffected by luteolin
treatment, which may imply that this selective GSK-3 inactivation can circumvent the
potential toxicity of more general GSK-3 inhibitors, which may inhibit Notch cleavage
(data not shown). Furthermore, there was a clear correlation between increases in
inactive and decreases in active GSK-3α (Figure 4.2c,f) following treatment, which
suggests that luteolin may affect the positive feedback loop of GSK-3 activation by
inactivating the PP1 phosphatase (Hirano et al., 2004). The direct targeting of this
feedback loop as a means to reduce GSK-3 activation seems highly probable in light of
the fact that calyculin A, a PP1 inhibitor, treatment has previously been found to increase
PS1 CTF phosphorylation (Buxbaum et al., 1990). Future studies will be needed to
further establish the molecular mechanism(s) whereby luteolin and diosmetin regulate
GSK-3 activity and consequently γ-secretase APP proteolysis.
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5.3 Potential of flavonoids as therapeutic interventions for AD

5.3.1 EGCG
Green tea contains numerous flavonoids and studies that have shown therapeutic
benefits of green tea generally do not identify the active component(s) responsible.
While EGCG promoted non-amyloidogenic proteolysis of APP, other flavonoids,
including GC and C, actually opposed this effect (Figure 3.1c and Figure 3.2f). This
finding suggests that the mixture of these flavonoids as found in whole green tea may
actually prevent or mask the beneficial properties of EGCG and may explain why
research involving green tea extracts or combinations of flavonoids results with such
variable findings (Chung et al., 2003). Furthermore, these findings may lead to the
generation of “optimized” green tea extracts, which yield the greatest therapeutic benefit
for AD. However, it may remain that a purified nutraceutical-grade formulation of
EGCG possesses the most efficacious anti-amyloidogenic properties.
While studies described in Chapter 3 confirm the promotion of nonamyloidogenic APP proteolysis and the consequent reductions in cerebral amyloidosis in
intracerebroventricular, intraperitoneal, and orally EGCG treated Tg APPsw mice, they
also suggest another potential means of neuroprotection afforded by EGCG treatment, a
reduction of potentially toxic sarkosyl-soluble phospho-tau isoforms. Despite the lack of
evidence for tangle formation and neuronal loss as mediators of cognitive impairment in
Tg APPsw mice, this AD model remains a useful tool in understanding the basis of tau
hyperphosphorylation. Furthermore, it is probable that soluble hyperphosphorylated
isoforms are ultimately the neurotoxic species of tau (Dickey et al., 2007; Kosik and
110

Shimura, 2005). Results clearly validate this possibility when comparing the high soluble
tau profiles of non-treated Tg APPsw mice to the much lower profiles of treated Tg APPsw
mice, which were nearly identical to the NT animals. It may also be likely that the P3
insoluble bands are comprised of less toxic ubiquinated phospho-tau isoforms, as
ubiquination has been previously found to shift soluble phosphorylated tau to insoluble
fractions (Kosik and Shimura, 2005). This shift may explain the elevated levels of
insoluble phospho-tau present in EGCG-treated and NT animals in relation to non-treated
Tg animals, as well as represent the basis of a biological means of compensating for an
abundance of toxic soluble phospho-tau isoforms (Figure 3.14). In a recent study by
Dickey and colleagues (2007), heat shock protein 90 (HSP90) inhibitors were found to
reduce levels of soluble phospho-tau isoforms by promoting turnover through an
increased rate of ubiquination and degradation via carboxy terminus of Hsp70-interacting
protein (CHIP). Interestingly, EGCG has been found to inhibit the activity of HSP90 by
directly binding to this chaperone protein (Palermo et al., 2005). For these reasons, it
may now be important to investigate CHIP-mediated ubiquination and HSP90 inhibition
as the means whereby EGCG modulates neurotoxic phospho-tau isoforms.
In addition to demonstrating the ability of chronic EGCG administration to
decrease brain levels of soluble hyperphosphorylated tau, these were the first studies
demonstrating that EGCG can have marked cognitive benefits in a transgenic model for
AD. Consistent with the findings detailed here, Haque and colleagues (2006) have
reported that rats given drinking water high in green tea catechins (mostly EGCG) for
5 months showed less memory impairment following intracerebroventricular injection of
Aβ1–40 compared to those given normal drinking water. Here, in a similar 6 month oral
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administration of EGCG to Tg APPsw mice not only reduced both cerebral amyloidosis in
cognitively-important brain areas, but also improved working memory performance to a
flawless/errorless level by the end of testing. Since prior studies have clearly shown a
strong and presumably causative relationship between brain Aβ levels and impaired
memory in the RAWM task (Arendash et al., 2001; Leighty et al., 2004), the ability of
orally administered EGCG to improve upon the already good RAWM performance of Tg
APPsw is most probably related in part to the anti-amyloidogenic effect of this treatment
through enhancement of α-secretase activity.
Indeed, the presently reported decreases in cerebral amyloidosis mediated by
chronic oral administration of EGCG are comparable to those induced by intraperitoneal
administration. Yet, the cognitive benefits of intraperitoneal EGCG administration were
more profound than those provided by oral EGCG administration, despite Tg animals in
both treatment paradigms being testing at the same 14 month age. This is most likely due
to the greater cognitive impairment manifested by the inbred Tg APPsw mice on a mixed
C57/B6/SJL/SW background (given intraperitoneal injected EGCG) compared to the
Tg2576/Taconic mice on a B6/SJL background (given orally administered EGCG). Even
in advanced age, mice primarily bearing a B6 background are unusually capable
performers in spatial tasks (King and Arendash, 2002). Thus, the mutant APPsw
transgene had not fully penetrated this B6 background by 14 months of age, resulting in
maintained RAWM performance in Tg controls. By contrast, it has been previously
reported that the inbred Tg APPsw mice exhibit cognitive impairment by 6–8 months of
age, before Aβ deposition is even evident (Arendash et al., 2004, 2006). In the
intraperitoneal study, inbred Tg APPsw mice began treatment at 12 months of age, long
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after they typically display cognitive impairment. Therefore, the substantial cognitive
benefits seen after 2 months of treatment suggest that EGCG could be an effective
treatment for established Alzheimer’s disease cases. Importantly and consequently, both
intraperitoneal and oral administration of EGCG provided cognitive benefit to AD
transgenic mice, suggesting oral EGCG treatment as a viable therapeutic approach
against AD pathology and associated cognitive impairment.
Major difficulties in preparing an effective therapeutic formulation of EGCG for
clinical trial stem from both the inherent differences in its metabolism between rodents
and humans as well as its poor oral bioavailability. For example, in one study that was
employed to formulate the concentration of EGCG in the drinking water, Lambert and
colleagues (2003) reported the oral bioavailability of free/unconjugated EGCG in mice
< 1% for a singly gavaged dose of 75 mg/kg. Furthermore, they found a large part (50–
90%) of orally administered EGCG became rapidly conjugated due to its exposure to
respective enzymes in the liver and small intestine (Lambert et al., 2003). In an earlier
study by Suganuma and colleagues (1998), EGCG was found to be primarily composed
of free/unconjugated EGCG in various tissues (including the brain) following gavage,
whereas the blood/plasma was composed of mostly conjugated forms. This study also
confirmed the blood - brain barrier permeability of EGCG. Conjugation of EGCG, which
includes methylation, glucuronidation, and sulfation, unfortunately reduces its half-life
from 18 hours down to < 4 hours. This conjugation is a limiting factor in both mice and
rats. On the other hand, human patients orally treated with EGCG present primarily free
EGCG (unconjugated ~77-100%), but still evidence its poor oral bioavailability (< 1%)
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(Lee et al., 2002). The potential effects of metabolites aside, the animal studies
conducted may be quite reflective and relevant to the human condition.
Importantly, the administration of EGCG in drinking water, wherein Tg APPsw
mice were continuously taking in EGCG, would appear to have circumvented its poor
oral bioavailability, as these mice evidenced both reduced cerebral amyloidosis and
cognitive benefit. However, Tg APPsw mice treated via intraperitoneal injection
presumably distribute free/unconjugated EGCG into the brain, where its direct action
occurs, more efficiently than oral administration because this route avoids first pass
metabolism. Whether this potential difference between intraperitoneal and oral
administration in the levels of free/unconjugated EGCG truly affects cognitive benefit
remains to be determined. Taking the aforementioned studies into account, along with
the fact that orally treated Tg APPsw mice received a dose spread throughout the daily
consumption of their drinking water, it is obvious that single-dose administration of
EGCG (gavaged or injected) would yield higher effective concentrations in these
animals. Therefore, when considering application in human clinical trials, a single oral
bolus of EGCG may be an effective dosing paradigm. Based on the faster metabolic rate
of mice, the doses employed in both the intraperitoneal and oral studies would be
equivalent to a ~ 1500 mg of EGCG daily intake in humans. Although not administered
on a chronic basis, oral doses of similar magnitudes have been used in clinical trial
(Ullmann et al., 2003). Taken together, these data prompt the need for future clinical
trials with a purified nutraceutical grade-EGCG or its structural analogs, which may
demonstrate more effective anti-amyloidogenic properties or possess better
bioavailabilities.
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5.3.2 5,7-Dihydroxyflavones
Although luteolin treatment markedly reduced both soluble Aβ1-40, 42 isoforms in
vivo (Figure 4.6f), its poor bioavailability makes it less attractive as a potential
nutraceutical for opposing AD pathogenesis. Like many aglycone forms of flavonoids,
luteolin potentially reaches its molecular target by passive diffusion through cell
membranes. This means of cellular uptake may explain the rapid onset of GSK-3α
inactivation as observed following luteolin treatment (Figure 4.2a,d) and, along with
findings in Figure 4.6, may indicate favorable blood - brain barrier permeability. It
would also appear that diosmetin, via its parent compound diosmin, may possess
favorable blood - brain barrier permeability as Aβ pathology is markedly reduced in
treated Tg APPsw mice (Figure 4.8). A micronized nutraceutical formulation of diosmin,
under the trade name Daflon, has been both safely and effectively used to treat chronic
venous disease and hemorrhoids for over a decade in Europe. Recently, improved
formulations of diosmin have been marketed in both Europe and the United States for
treatment of varicose and spider veins. However, these newer formulations may not
actually improve efficacy of diosmin, as diosmetin is likely the active compound
responsible for this nutraceutical’s therapeutic attributes. At the same time, clinical study
evaluating diosmin and its various formulations has already laid the groundwork for
future AD clinical trial. Based on the faster metabolic rate of the Tg APPsw mice, the
dose employed in the oral study would be equivalent to a ~1000 mg of diosmin daily
intake in humans. Future pre-clinical studies may be warranted, though, to assess any
cognitive benefits afforded by disomin/diosmetin treatment.
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5.4 Conclusions
Currently there are few treatment options for AD. Furthermore, those that have
been approved focus on the management of symptoms rather than the underlying
pathological mechanisms of the disease. While attempts at rational drug design against
amyloid pathology have appeared promising in pre-clinical studies, they have often fallen
short in clinical trials. Accordingly, natural compounds, which have been proven in
traditional medicine systems, are just beginning to be investigated as therapeutic
interventions for AD. The studies contained herein demonstrate that such natural
compounds can provide both neuropathologic, neurochemical, and cognitive benefits in
AD transgenic mice. These findings strongly argue for their continued investigation as a
safe and effective therapeutics against AD. Moreover, these flavonoids also proved to be
invaluable tools for studying the cellular and molecular mechanisms of AD. If Aβ
pathology in APPsw models is representative of disease pathology in the clinical
syndrome, then flavonoid administration to AD patients may be an effective prophylactic
strategy for reduction of both cerebral amyloidosis and tau pathology. Ultimately, the
identification of compounds that target multiple pathologies is essential for the
formulation of effective therapeutic interventions. For these reasons, EGCG, luteolin,
and diosmin/diosmetin may prove to be such effective compounds.
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